{"data": [{"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "ASH_hematology", "id": "84072624"}, {"start": 29, "end": 44, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 45, "end": 55, "username": "VincentRK", "id": "24261916"}]}, "text": "@chadinabhan @ASH_hematology @AaronGoodman33 @VincentRK Love it!", "source": "Twitter for iPhone", "created_at": "2022-12-10T02:20:59.000Z", "edit_history_tweet_ids": ["1601401559472304130"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601400573555019776"}], "id": "1601401559472304130", "in_reply_to_user_id": "2212735524", "conversation_id": "1601400573555019776"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 31, "end": 46, "username": "ASH_hematology", "id": "84072624"}, {"start": 59, "end": 74, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 81, "end": 91, "username": "VincentRK", "id": "24261916"}], "hashtags": [{"start": 47, "end": 53, "tag": "ASH22"}]}, "text": "RT @chadinabhan: Right here at @ASH_hematology #ASH22 with @AaronGoodman33 &amp; @VincentRK discussing science, mentorship, and music. \n\nGreat\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-10T02:20:55.000Z", "edit_history_tweet_ids": ["1601401542636371968"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601400573555019776"}], "id": "1601401542636371968", "conversation_id": "1601401542636371968"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "bdermanmd", "id": "872983600416862208"}], "annotations": [{"start": 208, "end": 210, "probability": 0.5628, "type": "Other", "normalized_text": "PFS"}]}, "text": "@bdermanmd Right, but with that analysis you select for a fitter population and forego the benefits of randomization. It\u2019s not a fair comparison anyways. For a fit motivated older patient who strongly values PFS, a transplant is reasonable.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:13:03.000Z", "edit_history_tweet_ids": ["1601369364842049536"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601369086243786753"}], "id": "1601369364842049536", "in_reply_to_user_id": "872983600416862208", "conversation_id": "1601305074629648385"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "strouse_chris", "id": "898851661"}, {"start": 15, "end": 30, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 31, "end": 43, "username": "nihardesai7", "id": "75550503"}], "annotations": [{"start": 61, "end": 65, "probability": 0.5094, "type": "Other", "normalized_text": "Chris"}]}, "text": "@strouse_chris @AaronGoodman33 @nihardesai7 I\u2019m in same boat Chris!", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:33:17.000Z", "edit_history_tweet_ids": ["1601344259499573249"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601342476056670208"}], "id": "1601344259499573249", "in_reply_to_user_id": "898851661", "conversation_id": "1601335757213696003"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "KonLontos", "id": "1541226866870292480"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@KonLontos @AaronGoodman33 I agree with waiting for full data. At some combination of age and frailty, this \u201csome point down the road\u201d becomes an unrealistic fantasy though. Further down the road, other therapies will also mature and be available.", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:28:38.000Z", "edit_history_tweet_ids": ["1601343090618355713"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601339797598965760"}], "id": "1601343090618355713", "in_reply_to_user_id": "1541226866870292480", "conversation_id": "1601335757213696003"}, {"entities": {"mentions": [{"start": 0, "end": 16, "username": "Balitsky_HemeMD", "id": "1153334819310505985"}, {"start": 17, "end": 27, "username": "HiraSMian", "id": "419595308"}]}, "text": "@Balitsky_HemeMD @HiraSMian Superstar indeed!", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:23:39.000Z", "edit_history_tweet_ids": ["1601341833237254145"], "author_id": "1269642863924609025", "lang": "nl", "referenced_tweets": [{"type": "replied_to", "id": "1601304691685691392"}], "id": "1601341833237254145", "in_reply_to_user_id": "1153334819310505985", "conversation_id": "1601304691685691392"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@nihardesai7 @AaronGoodman33 Trial enrolled a long time ago- 2009 was when it was first listed on the European trial registry", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:20:28.000Z", "edit_history_tweet_ids": ["1601341035296149504"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601338994280710144"}], "id": "1601341035296149504", "in_reply_to_user_id": "75550503", "conversation_id": "1601335757213696003"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "HematoRules", "id": "990578290690797570"}], "annotations": [{"start": 53, "end": 56, "probability": 0.5798, "type": "Other", "normalized_text": "MAIA"}, {"start": 65, "end": 68, "probability": 0.4658, "type": "Other", "normalized_text": "dara"}, {"start": 178, "end": 181, "probability": 0.5453, "type": "Other", "normalized_text": "dara"}, {"start": 183, "end": 185, "probability": 0.5059, "type": "Other", "normalized_text": "len"}]}, "text": "@HematoRules Hi- this trial enrolled long before the MAIA trial (dara/len/dex). \n\nHowever if anything the relative benefit offered by a transplant would be even less compared to dara/len/dex or velcade/len/dex.", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:06:48.000Z", "edit_history_tweet_ids": ["1601337592535883778"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601336310186520579"}], "id": "1601337592535883778", "in_reply_to_user_id": "990578290690797570", "conversation_id": "1601336310186520579"}, {"text": "Excited to moderate this session at #ASH22 at 4:00 pm tomorrow! Look forward to a robust discussion. \n\n#mmsm https://t.co/GUZumDyEVs", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 37, "end": 41, "probability": 0.5026, "type": "Other", "normalized_text": "ASH22"}, {"start": 104, "end": 107, "probability": 0.4782, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 109, "end": 132, "url": "https://t.co/GUZumDyEVs", "expanded_url": "https://twitter.com/mannimd1/status/1600482351523409920", "display_url": "twitter.com/mannimd1/statu\u2026"}], "hashtags": [{"start": 36, "end": 42, "tag": "ASH22"}, {"start": 103, "end": 108, "tag": "mmsm"}]}, "created_at": "2022-12-09T21:06:31.000Z", "edit_history_tweet_ids": ["1601322423848407040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600482351523409920"}], "id": "1601322423848407040", "conversation_id": "1601322423848407040"}, {"text": "I speak only for myself here- I recognize everyone has strong opinions about this. I meet patients according to their values/preferences- it is a nuanced discussion. Look forward to further discussion at the meeting.", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:58:28.000Z", "edit_history_tweet_ids": ["1601305297833799681"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601305074629648385"}], "id": "1601305297833799681", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1601305074629648385"}, {"text": "\u2b50\ufe0fPractice changing abstract\n\n\u2b50\ufe0fMel140 fails to beat len/dex in 60-75 year olds\n\nThis combined with lack of OS benefit to date in DETERMINATION/IFM 2009 has considerably lessened enthusiasm to transpl (esp mel140) standard risk #mmsm above age 70.\n\n#ASH22\nhttps://t.co/9NykX99A65", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 130, "end": 142, "probability": 0.5258, "type": "Other", "normalized_text": "DETERMINATION"}, {"start": 144, "end": 146, "probability": 0.7035, "type": "Other", "normalized_text": "IFM"}], "urls": [{"start": 256, "end": 279, "url": "https://t.co/9NykX99A65", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed M", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Research, clinical trials, adult, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Study Population, Human 1 Clinic of Hematology, Oncology and Stem Cell Transplantation, Muenchen Klinik Schwabing, Munich, Germany 2 Klinikum Nuernberg, Nuernberg,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html"}], "hashtags": [{"start": 228, "end": 233, "tag": "mmsm"}, {"start": 249, "end": 255, "tag": "ASH22"}]}, "created_at": "2022-12-09T19:57:35.000Z", "edit_history_tweet_ids": ["1601305074629648385"], "author_id": "1269642863924609025", "lang": "en", "id": "1601305074629648385", "conversation_id": "1601305074629648385"}, {"entities": {"mentions": [{"start": 105, "end": 116, "username": "UofUHealth", "id": "92088511"}], "urls": [{"start": 117, "end": 140, "url": "https://t.co/R2MfQxjFMs", "expanded_url": "https://twitter.com/ManniMD1/status/1601255320319205377/photo/1", "display_url": "pic.twitter.com/R2MfQxjFMs", "media_key": "3_1601255315357343750"}], "hashtags": [{"start": 28, "end": 34, "tag": "ASH22"}, {"start": 91, "end": 104, "tag": "lifeelevated"}]}, "text": "Heading to NOLA shortly for #ASH22 but getting some runs in before heading to the airport!\n#lifeelevated @UofUHealth https://t.co/R2MfQxjFMs", "source": "Twitter for iPhone", "created_at": "2022-12-09T16:39:52.000Z", "edit_history_tweet_ids": ["1601255320319205377"], "author_id": "1269642863924609025", "lang": "en", "id": "1601255320319205377", "conversation_id": "1601255320319205377"}, {"entities": {"mentions": [{"start": 28, "end": 40, "username": "HadidiSamer", "id": "774267564"}], "urls": [{"start": 65, "end": 88, "url": "https://t.co/NsSIACnhVI", "expanded_url": "https://twitter.com/hadidisamer/status/1601170628899323904", "display_url": "twitter.com/hadidisamer/st\u2026"}], "hashtags": [{"start": 59, "end": 64, "tag": "mmsm"}]}, "text": "A very thoughtful thread by @HadidiSamer on smoldering MM. #mmsm https://t.co/NsSIACnhVI", "source": "Twitter for iPhone", "created_at": "2022-12-09T13:56:10.000Z", "edit_history_tweet_ids": ["1601214122426650624"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601170628899323904"}], "id": "1601214122426650624", "conversation_id": "1601214122426650624"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "CoachBon", "id": "913851074"}], "annotations": [{"start": 16, "end": 21, "probability": 0.5174, "type": "Other", "normalized_text": "Bonnie"}]}, "text": "@CoachBon Coach Bonnie- I will write more about this after attending the presentation. I need to understand it better. Will keep you updated.", "source": "Twitter for iPhone", "created_at": "2022-12-09T02:31:41.000Z", "edit_history_tweet_ids": ["1601041864656052225"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600997558708760576"}], "id": "1601041864656052225", "in_reply_to_user_id": "913851074", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "JuliPerezBot", "id": "747629405225127940"}, {"start": 109, "end": 124, "username": "ASH_hematology", "id": "84072624"}, {"start": 127, "end": 136, "username": "n_gangat", "id": "2833103654"}], "annotations": [{"start": 39, "end": 43, "probability": 0.6408, "type": "Other", "normalized_text": "ASH22"}, {"start": 88, "end": 90, "probability": 0.5901, "type": "Other", "normalized_text": "ASH"}, {"start": 92, "end": 100, "probability": 0.5789, "type": "Other", "normalized_text": "New Daily"}], "hashtags": [{"start": 38, "end": 44, "tag": "ASH22"}]}, "text": "RT @JuliPerezBot: Getting excited for #ASH22 Check out the preview issue by our amazing ASH New Daily crew! \u2066@ASH_hematology\u2069 \u2066@n_gangat\u2069 \u2066\u2026", "source": "Twitter for iPhone", "created_at": "2022-12-09T02:15:56.000Z", "edit_history_tweet_ids": ["1601037903227891712"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1601008414762622977"}], "id": "1601037903227891712", "conversation_id": "1601037903227891712"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "RitaAssi4", "id": "1205790868730462213"}, {"start": 11, "end": 22, "username": "doctorpemm", "id": "2429552622"}, {"start": 23, "end": 34, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 35, "end": 49, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "text": "@RitaAssi4 @doctorpemm @Mohty_EBMT @Dr_AmerZeidan Sorry you couldn\u2019t make it! Will try my best to keep you updated (especially since you put my name up there with the legends!)", "source": "Twitter for iPhone", "created_at": "2022-12-09T01:45:31.000Z", "edit_history_tweet_ids": ["1601030248845299713"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601030075939311616"}], "id": "1601030248845299713", "in_reply_to_user_id": "1205790868730462213", "conversation_id": "1601030075939311616"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "kansagraMD", "id": "561122329"}], "annotations": [{"start": 94, "end": 96, "probability": 0.4262, "type": "Other", "normalized_text": "MRD"}, {"start": 125, "end": 129, "probability": 0.3623, "type": "Organization", "normalized_text": "CESAR"}]}, "text": "@kansagraMD And I appreciate you sharing this table- but a more relevant comparison is this:\n\nMRD neg rates post-ASCT in GEM-CESAR= 63%\nMRD neg rates post-ASCT in KRD arm of FORTE=83%.\n\nI will humbly admit that I am surprised and disappointed.", "source": "Twitter Web App", "created_at": "2022-12-09T01:42:05.000Z", "edit_history_tweet_ids": ["1601029382151098368"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601013460799614976"}], "id": "1601029382151098368", "in_reply_to_user_id": "561122329", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "Eddie_Cliff", "id": "74081884"}, {"start": 13, "end": 24, "username": "dgermain21", "id": "18821994"}], "annotations": [{"start": 53, "end": 57, "probability": 0.7374, "type": "Person", "normalized_text": "Eddie"}]}, "text": "@Eddie_Cliff @dgermain21 Can\u2019t wait to see you again Eddie!", "source": "Twitter for iPhone", "created_at": "2022-12-09T01:37:29.000Z", "edit_history_tweet_ids": ["1601028226683637760"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601020063590776832"}], "id": "1601028226683637760", "in_reply_to_user_id": "74081884", "conversation_id": "1601020063590776832"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "kansagraMD", "id": "561122329"}], "annotations": [{"start": 27, "end": 29, "probability": 0.6537, "type": "Other", "normalized_text": "MRD"}]}, "text": "@kansagraMD I do think the MRD negativity rates were much lower than expected. The thought process presumably was that it\u2019s earlier stage, and hence theoretically easier to \u201ceradicate/nip it in the bud\u201d. Will inquire further at the meeting, look forward to discussing.", "source": "Twitter for iPhone", "created_at": "2022-12-09T01:34:09.000Z", "edit_history_tweet_ids": ["1601027388229312512"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601013460799614976"}], "id": "1601027388229312512", "in_reply_to_user_id": "561122329", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "mattjbrunner", "id": "1105483475296178176"}], "annotations": [{"start": 96, "end": 102, "probability": 0.706, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@mattjbrunner One can argue that a similar (if not higher) ballpark percentage of patients with myeloma can be cured with todays therapies/available agents as well.", "source": "Twitter Web App", "created_at": "2022-12-08T20:11:06.000Z", "edit_history_tweet_ids": ["1600946090051719169"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600944799451738113"}], "id": "1600946090051719169", "in_reply_to_user_id": "1105483475296178176", "conversation_id": "1600938853308645376"}, {"text": "I would really love if someone with more expertise in #mmsm than me, would thoughtful engage on this thread- and offer their thoughts. Look forward to discussing at ASH as well.", "source": "Twitter Web App", "entities": {"annotations": [{"start": 55, "end": 58, "probability": 0.6676, "type": "Other", "normalized_text": "mmsm"}, {"start": 165, "end": 167, "probability": 0.7835, "type": "Organization", "normalized_text": "ASH"}], "hashtags": [{"start": 54, "end": 59, "tag": "mmsm"}]}, "created_at": "2022-12-08T19:53:02.000Z", "edit_history_tweet_ids": ["1600941543136710657"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600938853308645376"}], "id": "1600941543136710657", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600938853308645376"}, {"text": "Which is why the very low rates of sustained MRD negativity rates (23% on intent to treat) with an aggressive approach of KRD&gt;transplant&gt; maintenance is so troubling.\n\n#mmsm #ASH22\n\nhttps://t.co/2x1vesjxNo https://t.co/rpUH4UYKFX", "source": "Twitter Web App", "entities": {"annotations": [{"start": 45, "end": 47, "probability": 0.5594, "type": "Other", "normalized_text": "MRD"}, {"start": 122, "end": 124, "probability": 0.4572, "type": "Other", "normalized_text": "KRD"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/2x1vesjxNo", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}, {"start": 212, "end": 235, "url": "https://t.co/rpUH4UYKFX", "expanded_url": "https://twitter.com/chadinabhan/status/1600901994658418688", "display_url": "twitter.com/chadinabhan/st\u2026"}], "hashtags": [{"start": 174, "end": 179, "tag": "mmsm"}, {"start": 180, "end": 186, "tag": "ASH22"}]}, "created_at": "2022-12-08T19:42:21.000Z", "edit_history_tweet_ids": ["1600938853308645376"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600901994658418688"}], "id": "1600938853308645376", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 15, "end": 25, "username": "VincentRK", "id": "24261916"}, {"start": 26, "end": 36, "username": "myelomaMD", "id": "301568235"}]}, "text": "@BijoyTelivala @VincentRK @myelomaMD From a \"prognostic\" standpoint, outcomes similar whether you progress on 10mg of len or 25mg or len. I do not think this study answers the utility of a dose escalation of lenalidomide. Anecdotally, that can sometimes buy additional time, but I do not know or good evidence for it.", "source": "Twitter Web App", "created_at": "2022-12-08T17:56:48.000Z", "edit_history_tweet_ids": ["1600912290546520069"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600907245419900928"}], "id": "1600912290546520069", "in_reply_to_user_id": "964268621655695360", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 23, "username": "VincentRK", "id": "24261916"}, {"start": 24, "end": 34, "username": "myelomaMD", "id": "301568235"}]}, "text": "@HemSandoval @VincentRK @myelomaMD I meant *study*, not trial :)", "source": "Twitter Web App", "created_at": "2022-12-08T16:40:29.000Z", "edit_history_tweet_ids": ["1600893085038170118"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600889885212037130"}], "id": "1600893085038170118", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 23, "username": "VincentRK", "id": "24261916"}, {"start": 24, "end": 34, "username": "myelomaMD", "id": "301568235"}]}, "text": "@HemSandoval @VincentRK @myelomaMD This trial doesnt necessarily answer that question specifically. It is thought provoking though.", "source": "Twitter Web App", "created_at": "2022-12-08T16:27:46.000Z", "edit_history_tweet_ids": ["1600889885212037130"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600879155930755072"}], "id": "1600889885212037130", "in_reply_to_user_id": "4067920889", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 231, "end": 246, "username": "rajshekharucms", "id": "140966169"}, {"start": 247, "end": 259, "username": "Eddie_Cliff", "id": "74081884"}, {"start": 260, "end": 275, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 19, "end": 21, "probability": 0.6415, "type": "Other", "normalized_text": "MRD"}, {"start": 37, "end": 41, "probability": 0.6262, "type": "Other", "normalized_text": "ASH22"}, {"start": 80, "end": 82, "probability": 0.6828, "type": "Other", "normalized_text": "MRD"}, {"start": 122, "end": 125, "probability": 0.5103, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 206, "end": 229, "url": "https://t.co/pE5anOaVg9", "expanded_url": "https://www.nature.com/articles/s41408-022-00750-1", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600868821236998144/O4s59sb6?format=jpg&name=orig", "width": 1970, "height": 1517}, {"url": "https://pbs.twimg.com/news_img/1600868821236998144/O4s59sb6?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015\u20132020", "description": "Blood Cancer Journal - Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015\u20132020", "unwound_url": "https://www.nature.com/articles/s41408-022-00750-1?error=cookies_not_supported&code=5043ea74-3a43-4969-85e8-fa0b6d08d74d"}, {"start": 276, "end": 299, "url": "https://t.co/pkTzoCVPbe", "expanded_url": "https://twitter.com/ManniMD1/status/1600868817608925184/photo/1", "display_url": "pic.twitter.com/pkTzoCVPbe", "media_key": "3_1600868638340239360"}], "hashtags": [{"start": 36, "end": 42, "tag": "ASH22"}, {"start": 121, "end": 126, "tag": "mmsm"}]}, "text": "As you prepare for MRD abstracts at #ASH22, here is our paper that explains how MRD has been used in the last 5 years of #mmsm trials, and the limitations. Thankfully, more \"actionable\" trials on the way!\n\nhttps://t.co/pE5anOaVg9\n\n@rajshekharucms @Eddie_Cliff @AaronGoodman33 https://t.co/pkTzoCVPbe", "source": "Twitter Web App", "created_at": "2022-12-08T15:04:03.000Z", "edit_history_tweet_ids": ["1600868817608925184"], "author_id": "1269642863924609025", "lang": "en", "id": "1600868817608925184", "conversation_id": "1600868817608925184"}, {"entities": {"mentions": [{"start": 19, "end": 29, "username": "VincentRK", "id": "24261916"}, {"start": 30, "end": 40, "username": "myelomaMD", "id": "301568235"}], "urls": [{"start": 237, "end": 260, "url": "https://t.co/D2NFxIs6a7", "expanded_url": "https://ashpublications.org/blood/article/140/Supplement%201/9998/490520/Outcomes-of-Multiple-Myeloma-Patients-Refractory", "display_url": "ashpublications.org/blood/article/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600848903598796800/sp4KpeYk?format=png&name=orig", "width": 520, "height": 709}, {"url": "https://pbs.twimg.com/news_img/1600848903598796800/sp4KpeYk?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide", "description": "Background: Lenalidomide (Len) containing regimens are extensively used as first line therapy in multiple myeloma (MM). Since most patients (pts) eventually rel", "unwound_url": "https://ashpublications.org/blood/article/140/Supplement%201/9998/490520/Outcomes-of-Multiple-Myeloma-Patients-Refractory"}], "hashtags": [{"start": 262, "end": 268, "tag": "ASH22"}, {"start": 270, "end": 275, "tag": "mmsm"}]}, "text": "Useful abstract by @VincentRK @myelomaMD seems to indicate that lenalidomide refractoriness is not a dose dependent (len 10mg vs 25mg) phenomena.\n\nSubsequent outcomes similar whether progressing on low dose of len or full dose of len. \n\nhttps://t.co/D2NFxIs6a7\n\n#ASH22 \n#mmsm", "source": "Twitter Web App", "created_at": "2022-12-08T13:44:43.000Z", "edit_history_tweet_ids": ["1600848852235403264"], "author_id": "1269642863924609025", "lang": "en", "id": "1600848852235403264", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 86, "username": "DavidSteensma", "id": "2739065578"}, {"start": 87, "end": 97, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 98, "end": 111, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 112, "end": 122, "username": "VincentRK", "id": "24261916"}, {"start": 123, "end": 133, "username": "myelomaMD", "id": "301568235"}, {"start": 134, "end": 143, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 208, "end": 215, "probability": 0.7578, "type": "Other", "normalized_text": "ASH News"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy And to answer your Q, this year I reviewed abstracts/ served on ASH News team- so spent a lot of time scrolling through oral/poster sessions for various diseases. As I am a clinician, I rely on others to inform me about relevant basic research, and focus energy on clinical stuff.", "source": "Twitter Web App", "created_at": "2022-12-08T04:19:08.000Z", "edit_history_tweet_ids": ["1600706518030356480"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600705945558224896"}], "id": "1600706518030356480", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 86, "username": "DavidSteensma", "id": "2739065578"}, {"start": 87, "end": 97, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 98, "end": 111, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 112, "end": 122, "username": "VincentRK", "id": "24261916"}, {"start": 123, "end": 133, "username": "myelomaMD", "id": "301568235"}, {"start": 134, "end": 143, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 338, "end": 344, "probability": 0.6744, "type": "Other", "normalized_text": "twitter"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy Theres great advice already given here by people smarter than me.\n\nMost importantly, reassure yourself that something truly practice changing will find your attention through news/conversations/twitter. You wont miss it. I recommend focusing on networking/socializing/having fun\ud83d\ude00", "source": "Twitter Web App", "created_at": "2022-12-08T04:16:51.000Z", "edit_history_tweet_ids": ["1600705945558224896"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600705945558224896", "in_reply_to_user_id": "626650397", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "HiraSMian", "id": "419595308"}]}, "text": "@HiraSMian I have full day clinic tomorrow too! \ud83d\ude41", "source": "Twitter Web App", "created_at": "2022-12-08T03:34:00.000Z", "edit_history_tweet_ids": ["1600695160878223360"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600685500339171330"}], "id": "1600695160878223360", "in_reply_to_user_id": "419595308", "conversation_id": "1600685500339171330"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "psharmaMD", "id": "3018932371"}, {"start": 15, "end": 24, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 25, "end": 33, "username": "iStopMM", "id": "844232399319941122"}, {"start": 34, "end": 48, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 88, "end": 91, "probability": 0.9175, "type": "Place", "normalized_text": "Utah"}]}, "text": "RT @psharmaMD: @ManniMD1 @iStopMM @sykristinsson Very nice! We are changing practice in Utah for sure :). I gave a short 15 mins talk to PC\u2026", "source": "Twitter Web App", "created_at": "2022-12-07T20:19:04.000Z", "edit_history_tweet_ids": ["1600585704588787712"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600579488911216640"}], "id": "1600585704588787712", "conversation_id": "1600585704588787712"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "AJurczyszyn", "id": "1163750299"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 37, "username": "iStopMM", "id": "844232399319941122"}, {"start": 38, "end": 52, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 76, "end": 78, "probability": 0.4518, "type": "Other", "normalized_text": "ASH"}, {"start": 135, "end": 137, "probability": 0.4405, "type": "Organization", "normalized_text": "ASH"}]}, "text": "@AJurczyszyn @AaronGoodman33 @iStopMM @sykristinsson I will email you after ASH as well. Please do DM me your email. And if you are at ASH, would love to meet!\n\nThanks", "source": "Twitter Web App", "created_at": "2022-12-07T18:35:58.000Z", "edit_history_tweet_ids": ["1600559759417303040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600558207487082496"}], "id": "1600559759417303040", "in_reply_to_user_id": "1163750299", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 30, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 31, "end": 39, "username": "iStopMM", "id": "844232399319941122"}, {"start": 40, "end": 53, "username": "ingigerdursv", "id": "740181058210107392"}, {"start": 141, "end": 154, "username": "ingigerdursv", "id": "740181058210107392"}]}, "text": "@sykristinsson @AaronGoodman33 @iStopMM @ingigerdursv I wish this was an oral session, but I will be sure to drop by and give a shout-out to @ingigerdursv's poster, its one of the most practice informing/changing sessions at this entire meeting.", "source": "Twitter Web App", "created_at": "2022-12-07T17:48:43.000Z", "edit_history_tweet_ids": ["1600547870926868481"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600547436505743365"}], "id": "1600547870926868481", "in_reply_to_user_id": "3078258341", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 24, "username": "iStopMM", "id": "844232399319941122"}, {"start": 25, "end": 39, "username": "sykristinsson", "id": "3078258341"}, {"start": 78, "end": 92, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 62, "end": 64, "probability": 0.4606, "type": "Other", "normalized_text": "ASH"}]}, "text": "@AaronGoodman33 @iStopMM @sykristinsson I will send after the ASH meeting, as @sykristinsson was kind enough to share some confidential slides that I used. I will share after the meeting \ud83d\ude00", "source": "Twitter Web App", "created_at": "2022-12-07T17:43:30.000Z", "edit_history_tweet_ids": ["1600546555081027584"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600546340873781248"}], "id": "1600546555081027584", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 125, "end": 133, "username": "iStopMM", "id": "844232399319941122"}, {"start": 134, "end": 148, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 231, "end": 235, "probability": 0.6187, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 151, "end": 174, "url": "https://t.co/6Fok0TBUDi", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 2,3, S\u00e6mundur R\u00f6gnvaldsson, MD 4 *, Thor Aspelund, PhD 2 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi \u00d6nundarson, MD 5 *, Bjarni Agnarsson, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html"}, {"start": 246, "end": 269, "url": "https://t.co/QUlXawKR7Z", "expanded_url": "https://twitter.com/ManniMD1/status/1600545405540126720/photo/1", "display_url": "pic.twitter.com/QUlXawKR7Z", "media_key": "3_1600545179307425792"}], "hashtags": [{"start": 230, "end": 236, "tag": "ASH22"}]}, "text": "The title of my talk today to rheumatologists, we are already changing practice and minds as a result of the amazing work by @iStopMM @sykristinsson \n\nhttps://t.co/6Fok0TBUDi\n\nAn example of practice changed even before the actual #ASH22 meeting! https://t.co/QUlXawKR7Z", "source": "Twitter Web App", "created_at": "2022-12-07T17:38:56.000Z", "edit_history_tweet_ids": ["1600545405540126720"], "author_id": "1269642863924609025", "lang": "en", "id": "1600545405540126720", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}, {"start": 13, "end": 28, "username": "PallawiTorkaMD", "id": "918471705408016384"}, {"start": 29, "end": 45, "username": "PrashantTembha1", "id": "1160422800709959680"}, {"start": 46, "end": 62, "username": "DrRahulBhargav1", "id": "1125993236105875458"}, {"start": 63, "end": 75, "username": "Prasshmehta", "id": "1131767204972716032"}, {"start": 76, "end": 89, "username": "DrSwami_Iyer", "id": "91581868"}, {"start": 90, "end": 102, "username": "NitinJainMD", "id": "2756778469"}, {"start": 103, "end": 116, "username": "BldCancerDoc", "id": "2809497047"}, {"start": 186, "end": 198, "username": "nihardesai7", "id": "75550503"}], "annotations": [{"start": 149, "end": 155, "probability": 0.5727, "type": "Other", "normalized_text": "ASH2023"}], "hashtags": [{"start": 148, "end": 156, "tag": "ASH2023"}]}, "text": "@nihardesai7 @PallawiTorkaMD @PrashantTembha1 @DrRahulBhargav1 @Prasshmehta @DrSwami_Iyer @NitinJainMD @BldCancerDoc I\u2019m already looking forward to #ASH2023 to get to meet you in person @nihardesai7", "source": "Twitter Web App", "created_at": "2022-12-07T13:46:19.000Z", "edit_history_tweet_ids": ["1600486869539516416"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600486501405450240"}], "id": "1600486869539516416", "in_reply_to_user_id": "75550503", "conversation_id": "1600485048020615170"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "ShakiraG_MBBS", "id": "1194921398059311104"}, {"start": 15, "end": 25, "username": "stuchman1", "id": "487185530"}], "urls": [{"start": 26, "end": 49, "url": "https://t.co/JchDFOHaYC", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170394.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: \"You Have Your Knowledge, but I Have My Knowledge of My Body\": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 905. Outcomes Research\u2014Lymphoid Malignancies: Patient Representatio n and Equity in Hematologic Malignancies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) Shakira J. Grant, MBBS 1,2, Milenka Jean-Baptiste, MPH 3 *, Mykela Moore, BA 3 *, Jiona Mills, BSPH 3 *, Lauren Bates, MA 4 *, Sascha A. Tuchman, MD, MHS 1,5 and Paul Mihas, MA 6 * 1 Lineberger Comprehensive Cancer", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170394.html"}]}, "text": "@ShakiraG_MBBS @stuchman1 https://t.co/JchDFOHaYC\n\n^ and another excellent oral presentation by same group.", "source": "Twitter Web App", "created_at": "2022-12-07T13:32:19.000Z", "edit_history_tweet_ids": ["1600483344528965633"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600482351523409920"}], "id": "1600483344528965633", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600482351523409920"}, {"entities": {"mentions": [{"start": 243, "end": 257, "username": "ShakiraG_MBBS", "id": "1194921398059311104"}, {"start": 258, "end": 268, "username": "stuchman1", "id": "487185530"}], "annotations": [{"start": 21, "end": 24, "probability": 0.5786, "type": "Other", "normalized_text": "mmsm"}, {"start": 49, "end": 53, "probability": 0.7328, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 218, "end": 241, "url": "https://t.co/QJR4sU8GvB", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167763.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: \"If You Don\u2019t Trust Your Doctor That Much...You\u2019d Feel Less Confident Doing a Research Study\": Factors Influencing Black Patient Participation in Hematology Trials", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 905. Outcomes Research\u2014Lymphoid Ma lignancies: Patient Representation and Equity in Hematologic Malignancies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) Shakira J. Grant, MBBS 1,2, Milenka Jean-Baptiste, MPH 3 *, Mykela Moore, BA 3 *, Jiona Mills, BSPH 3 *, Lauren Bates, MA 4 *, Sascha A. Tuchman, MD, MHS 1,2 and Paul Mihas, MA 5 * 1 Lineberger Comprehensive Cancer", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167763.html"}, {"start": 269, "end": 292, "url": "https://t.co/aw10T0N8qj", "expanded_url": "https://twitter.com/ManniMD1/status/1600482351523409920/photo/1", "display_url": "pic.twitter.com/aw10T0N8qj", "media_key": "3_1600482116734636032"}], "hashtags": [{"start": 20, "end": 25, "tag": "mmsm"}, {"start": 48, "end": 54, "tag": "ASH22"}]}, "text": "Perhaps my favorite #mmsm disparity research at #ASH22.\n\nRather than comparing outcomes between races in another dataset, or describing low enrollment in trials, this study helps us understand the \u201cwhy\u201d of the story.\n\nhttps://t.co/QJR4sU8GvB\n\n@ShakiraG_MBBS @stuchman1 https://t.co/aw10T0N8qj", "source": "Twitter Web App", "created_at": "2022-12-07T13:28:22.000Z", "edit_history_tweet_ids": ["1600482351523409920"], "author_id": "1269642863924609025", "lang": "en", "id": "1600482351523409920", "conversation_id": "1600482351523409920"}, {"text": "The presence or absence of gain1q did not change outcomes in a cohort of patients with relapsed myeloma receiving daratumumab- data from the Mayo dataset.\n\nIMO- Anti-CD38 therapy similarly effective in gain1q, whether you choose isa or dara. \n\nhttps://t.co/hMfWRSn6tN\n\n#ASH22", "source": "Twitter Web App", "entities": {"annotations": [{"start": 96, "end": 102, "probability": 0.6041, "type": "Other", "normalized_text": "myeloma"}, {"start": 114, "end": 124, "probability": 0.4996, "type": "Other", "normalized_text": "daratumumab"}, {"start": 141, "end": 144, "probability": 0.4638, "type": "Other", "normalized_text": "Mayo"}, {"start": 165, "end": 165, "probability": 0.5268, "type": "Other", "normalized_text": "-"}], "urls": [{"start": 244, "end": 267, "url": "https://t.co/hMfWRSn6tN", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169533.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Ricardo D Parrondo, MD 1, Lindsay Brooke Gardner, MS, MD 1, Mohamad Alhaj Moustafa, MD 1, Vivek Roy, MD 2, Taimur Sher, MD 1, Ahsan Rasheed 2 *, Rahma M Warsame, MD 3, Jeremy T. Larsen 4 *, Wilson I. Gonsalves, MD 5, Taxiarchis Kourelis, MD 5, Prashant Kapoor, MD 3, Rafael Fonseca, MD 4, Asher Chanan-Khan, MD 2 and Sikander Ailawadhi 6 1 Division of Hematology and Medical", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169533.html"}], "hashtags": [{"start": 269, "end": 275, "tag": "ASH22"}]}, "created_at": "2022-12-07T13:12:42.000Z", "edit_history_tweet_ids": ["1600478408659517440"], "author_id": "1269642863924609025", "lang": "en", "id": "1600478408659517440", "conversation_id": "1600478408659517440"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "RahulDoc2", "id": "1336329089100046339"}]}, "text": "@RahulDoc2 Thanks for your reply on this tweet- that truly is a tough situation, hopefully you will find the information from the abstract useful during the consent process.", "source": "Twitter for iPhone", "created_at": "2022-12-07T04:15:37.000Z", "edit_history_tweet_ids": ["1600343245967409153"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600323073173258245"}], "id": "1600343245967409153", "in_reply_to_user_id": "1336329089100046339", "conversation_id": "1600320621426397184"}, {"text": "Good reminder of limited role of allogenic transplant in multiple myeloma- Mayo Clinic experience\n\nN=89\nLong term survival in less than 20%\nBy 2 years, 75% pts either progressed or died\n\nCaveat:most patients at relapse, not 1st remission\n\nhttps://t.co/TRmA2IIBMa\n\n#mmsm \n#ASH22 https://t.co/KDYAfJRqgU", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 66, "end": 85, "probability": 0.6851, "type": "Other", "normalized_text": "myeloma- Mayo Clinic"}, {"start": 265, "end": 268, "probability": 0.4892, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 239, "end": 262, "url": "https://t.co/TRmA2IIBMa", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper156078.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Research, Biological therapies, Clinical Research, health outcomes research, Therapies, Transplantation 1 Mayo Clinic Alix School of Medicine, Rochester, MN 2 Mayo clinic college of medicine, Rochester, MN 3 Division of Hematology, Mayo Clinic, Rochester, MN 4 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper156078.html"}, {"start": 278, "end": 301, "url": "https://t.co/KDYAfJRqgU", "expanded_url": "https://twitter.com/ManniMD1/status/1600320621426397184/photo/1", "display_url": "pic.twitter.com/KDYAfJRqgU", "media_key": "3_1600320617927958528"}], "hashtags": [{"start": 264, "end": 269, "tag": "mmsm"}, {"start": 271, "end": 277, "tag": "ASH22"}]}, "created_at": "2022-12-07T02:45:43.000Z", "edit_history_tweet_ids": ["1600320621426397184"], "author_id": "1269642863924609025", "lang": "en", "id": "1600320621426397184", "conversation_id": "1600320621426397184"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}, {"start": 24, "end": 36, "username": "asdisrosa78", "id": "3050942903"}, {"start": 37, "end": 53, "username": "SigrunThorstei1", "id": "1198917648630919168"}, {"start": 54, "end": 66, "username": "ThorvardurL", "id": "1199342830180651009"}, {"start": 67, "end": 78, "username": "thorirlong", "id": "3009607268"}, {"start": 79, "end": 95, "username": "eliaseythorsson", "id": "133109181"}, {"start": 96, "end": 108, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 109, "end": 124, "username": "PalmasonRobert", "id": "1291096121733939202"}, {"start": 125, "end": 133, "username": "jthorir", "id": "247118539"}, {"start": 134, "end": 146, "username": "astrunhelga", "id": "2758432772"}, {"start": 147, "end": 160, "username": "ingigerdursv", "id": "740181058210107392"}], "annotations": [{"start": 179, "end": 186, "probability": 0.4863, "type": "Other", "normalized_text": "Sigurdur"}, {"start": 219, "end": 221, "probability": 0.3263, "type": "Organization", "normalized_text": "ASH"}]}, "text": "@sykristinsson @iStopMM @asdisrosa78 @SigrunThorstei1 @ThorvardurL @thorirlong @eliaseythorsson @SaemundurMD @PalmasonRobert @jthorir @astrunhelga @ingigerdursv So inspirational, Sigurdur! Look forward to seeing you at ASH.", "source": "Twitter Web App", "created_at": "2022-12-06T13:48:37.000Z", "edit_history_tweet_ids": ["1600125059020247040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600123462827184128"}], "id": "1600125059020247040", "in_reply_to_user_id": "3078258341", "conversation_id": "1600123462827184128"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "sykristinsson", "id": "3078258341"}, {"start": 23, "end": 31, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 81, "end": 85, "probability": 0.6608, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 80, "end": 86, "tag": "ASH22"}]}, "text": "RT @sykristinsson: The @iStopMM team is very excited to present our findings at #ASH22\n\nPresentations from the study are, like before, prim\u2026", "source": "Twitter Web App", "created_at": "2022-12-06T13:47:04.000Z", "edit_history_tweet_ids": ["1600124669125832711"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600123462827184128"}], "id": "1600124669125832711", "conversation_id": "1600124669125832711"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "rajshekharucms", "id": "140966169"}, {"start": 16, "end": 24, "username": "mtmdphd", "id": "190337035"}], "annotations": [{"start": 35, "end": 37, "probability": 0.6092, "type": "Person", "normalized_text": "Raj"}]}, "text": "@rajshekharucms @mtmdphd Thank you Raj for your kind words and for sharing!", "source": "Twitter Web App", "created_at": "2022-12-06T03:10:40.000Z", "edit_history_tweet_ids": ["1599964515030163456"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599921424277250050"}], "id": "1599964515030163456", "in_reply_to_user_id": "140966169", "conversation_id": "1599921424277250050"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "KRakszawski", "id": "284694610"}]}, "text": "@KRakszawski May the force be with you!", "source": "Twitter Web App", "created_at": "2022-12-06T02:15:32.000Z", "edit_history_tweet_ids": ["1599950638271844352"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599948855797170176"}], "id": "1599950638271844352", "in_reply_to_user_id": "284694610", "conversation_id": "1599948855797170176"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "BijoyTelivala", "id": "964268621655695360"}, {"start": 15, "end": 25, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 35, "end": 37, "probability": 0.4852, "type": "Other", "normalized_text": "DRd"}, {"start": 40, "end": 43, "probability": 0.3726, "type": "Place", "normalized_text": "MAIA"}, {"start": 122, "end": 124, "probability": 0.4104, "type": "Other", "normalized_text": "DRd"}]}, "text": "@BijoyTelivala @VincentRK Yes, but DRd (MAIA) was studied in transplant ineligible patients. We don\u2019t have robust data on DRd for transplant eligible patients. The data for quads in \u201ctransplant eligible\u201d is stronger (with limitations of surrogates) than the data for DRd.", "source": "Twitter Web App", "created_at": "2022-12-06T00:06:53.000Z", "edit_history_tweet_ids": ["1599918264502870016"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599915232733761536"}], "id": "1599918264502870016", "in_reply_to_user_id": "964268621655695360", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 14, "end": 21, "probability": 0.5562, "type": "Person", "normalized_text": "Rajkumar"}, {"start": 79, "end": 81, "probability": 0.6181, "type": "Other", "normalized_text": "DRd"}, {"start": 92, "end": 96, "probability": 0.6232, "type": "Other", "normalized_text": "D-RVD"}]}, "text": "@VincentRK Dr Rajkumar, could you explain the thought process behind including DRd (but not D-RVD) for newly diagnosed standard risk MM?\n\nAppreciate it.", "source": "Twitter Web App", "created_at": "2022-12-05T23:44:30.000Z", "edit_history_tweet_ids": ["1599912628138430465"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599838360419213312"}], "id": "1599912628138430465", "in_reply_to_user_id": "24261916", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 24, "username": "EhsanMalekMD", "id": "3344279667"}, {"start": 25, "end": 40, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 41, "end": 55, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 56, "end": 68, "username": "End_myeloma", "id": "2538011298"}], "annotations": [{"start": 96, "end": 103, "probability": 0.568, "type": "Other", "normalized_text": "Rajkumar"}]}, "text": "@VincentRK @EhsanMalekMD @AaronGoodman33 @SagarLonialMD @End_myeloma I appreciate your reply Dr Rajkumar! Thank you. Do you have more information on the characteristics of these renal events in the control arm? Level of creatinine elevation. Did anyone end up on dialysis? Did they recover with initiation of myeloma treatment? Would be useful info.", "source": "Twitter Web App", "created_at": "2022-12-05T20:07:08.000Z", "edit_history_tweet_ids": ["1599857925492977664"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599855963543986178"}], "id": "1599857925492977664", "in_reply_to_user_id": "24261916", "conversation_id": "1598826846082121728"}, {"entities": {"mentions": [{"start": 15, "end": 30, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 92, "end": 98, "username": "Optum", "id": "318007077"}], "annotations": [{"start": 145, "end": 150, "probability": 0.4904, "type": "Other", "normalized_text": "cancer"}], "urls": [{"start": 236, "end": 259, "url": "https://t.co/WtFwkcYCg1", "expanded_url": "https://twitter.com/AaronGoodman33/status/1598819684610347014", "display_url": "twitter.com/AaronGoodman33\u2026"}]}, "text": "You were right @AaronGoodman33 \n\nThe DM was pure optics- nothing productive came out of it. @Optum took the weekend off, while our patients with cancer stayed in a limbo about whether their necessary treatment would be approved or not. https://t.co/WtFwkcYCg1", "source": "Twitter Web App", "created_at": "2022-12-05T18:03:23.000Z", "edit_history_tweet_ids": ["1599826784786477057"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1598819684610347014"}], "id": "1599826784786477057", "conversation_id": "1599826784786477057"}, {"text": "#ASH22 starts this week.\n\nHere is a list of top 10 abstracts that have already influenced my thought and practice in myeloma! Look forward to hearing more about these and other studies at the meeting!\n\n#mmsm https://t.co/mmiGmXbiUG", "source": "Twitter Web App", "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.6643, "type": "Other", "normalized_text": "ASH22"}, {"start": 117, "end": 123, "probability": 0.7147, "type": "Other", "normalized_text": "myeloma"}, {"start": 203, "end": 206, "probability": 0.4725, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 208, "end": 231, "url": "https://t.co/mmiGmXbiUG", "expanded_url": "https://twitter.com/ManniMD1/status/1590440063263182851", "display_url": "twitter.com/ManniMD1/statu\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}, {"start": 202, "end": 207, "tag": "mmsm"}]}, "created_at": "2022-12-05T14:55:42.000Z", "edit_history_tweet_ids": ["1599779550753193985"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1590440063263182851"}], "id": "1599779550753193985", "conversation_id": "1599779550753193985"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 117, "end": 125, "probability": 0.5542, "type": "Other", "normalized_text": "Dr Lonial"}]}, "text": "@RnInfection @AaronGoodman33 Also, I am nowhere near the level of expertise of the other people you\u2019ve asked such as Dr Lonial, so take what I say with a grain of salt.", "source": "Twitter Web App", "created_at": "2022-12-04T22:45:11.000Z", "edit_history_tweet_ids": ["1599535316133908480"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599534700225495040"}], "id": "1599535316133908480", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@RnInfection @AaronGoodman33 Ultimately, it is a complex nuanced decision, but there is enough ambiguity here that observing without treatment is a fully appropriate decision that I support when my patients make it. 3/end", "source": "Twitter Web App", "created_at": "2022-12-04T22:42:45.000Z", "edit_history_tweet_ids": ["1599534700225495040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599534249593696256"}], "id": "1599534700225495040", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@RnInfection @AaronGoodman33 Data from the German group highlighted in a recent thread I shared indicates that renal failure and compression fractures in absence of preceding lytic lesions are rare. Providing this information provides reassurance to my patients and I try to mention. 2/", "source": "Twitter Web App", "created_at": "2022-12-04T22:40:57.000Z", "edit_history_tweet_ids": ["1599534249593696256"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599533907145535488"}], "id": "1599534249593696256", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 68, "end": 74, "probability": 0.934, "type": "Other", "normalized_text": "twitter"}, {"start": 174, "end": 176, "probability": 0.6653, "type": "Other", "normalized_text": "SMM"}]}, "text": "@RnInfection @AaronGoodman33 It is tough to answer this w nuance on twitter. In general, depends on patient values/preferences. Every single time, when I\u2019ve seen a high risk SMM and discussed data on len, they\u2019ve elected to observe. \n\nThere is a 2/20/20+cytogenetics model, but also with same limitations. 1/", "source": "Twitter Web App", "created_at": "2022-12-04T22:39:36.000Z", "edit_history_tweet_ids": ["1599533907145535488"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599498447387734016"}], "id": "1599533907145535488", "in_reply_to_user_id": "327808606", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 43, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 44, "end": 56, "username": "RnInfection", "id": "327808606"}], "urls": [{"start": 148, "end": 171, "url": "https://t.co/EgYLWdLBjS", "expanded_url": "https://twitter.com/ManniMD1/status/1594140708679868416?s=20&t=IqviYwcafvhysoZU3HFdug", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "@RnInfection @AaronGoodman33 @DrOlaLandgren @RnInfection - hopefully this paper (and thread to explain it) will provide you with some reassurance.\n\nhttps://t.co/EgYLWdLBjS", "source": "Twitter Web App", "created_at": "2022-12-04T21:55:52.000Z", "edit_history_tweet_ids": ["1599522901522538496"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1594140708679868416"}, {"type": "replied_to", "id": "1599037186766036993"}], "id": "1599522901522538496", "in_reply_to_user_id": "327808606", "conversation_id": "1598826846082121728"}, {"text": "Highlights the power of mentorship in an inter-connected global era, where a lot of it can be done remotely! Kudos to all these trainees.\n\nThanks for reading! Look forward to seeing you soon at #ASH22.\n\nEND.", "source": "Twitter Web App", "entities": {"annotations": [{"start": 195, "end": 199, "probability": 0.5833, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 194, "end": 200, "tag": "ASH22"}]}, "created_at": "2022-12-04T17:40:28.000Z", "edit_history_tweet_ids": ["1599458630704992257"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458629513773056"}], "id": "1599458630704992257", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"text": "5. There is only one poster that I present myself (on the role of anti-CD38 therapy in 11;14 myeloma), meet me at that Session in Hall D on Saturday 5:30 pm . Manuscript already accepted at Blood Cancer Journal, I will share a thread soon!\n\nhttps://t.co/AVYiHqpdgd", "source": "Twitter Web App", "entities": {"annotations": [{"start": 93, "end": 99, "probability": 0.472, "type": "Other", "normalized_text": "myeloma"}, {"start": 190, "end": 209, "probability": 0.9535, "type": "Other", "normalized_text": "Blood Cancer Journal"}], "urls": [{"start": 241, "end": 264, "url": "https://t.co/AVYiHqpdgd", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165541.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy", "description": "Program: Oral and Poster Abstracts Session: 905. Outcomes Research\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Research, health outcomes research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Ghulam Rehman Mohyuddin, MD 1, Rajshekhar Chakraborty, MD 2, Gregory Calip, PhD 3 *, Mustafa S Ascha, PhD, MS 4 *, Xiaoliang Wang, PhD, MPH 5 *, Samuel Rubinstein, MD 6 *, Sascha A. Tuchman, MD, MHS 7, Luciano J. Megala Costa, MD, PhD 8, Benjamin Haaland 9 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165541.html"}]}, "created_at": "2022-12-04T17:40:28.000Z", "edit_history_tweet_ids": ["1599458629513773056"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458628410675200"}], "id": "1599458629513773056", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 19, "end": 30, "username": "AlecBritt4", "id": "1230155192374644736"}], "annotations": [{"start": 73, "end": 79, "probability": 0.6586, "type": "Other", "normalized_text": "myeloma"}, {"start": 135, "end": 137, "probability": 0.7135, "type": "Other", "normalized_text": "MRD"}]}, "text": "4. I did work with @AlecBritt4 on the landscape of maintenance trials in myeloma, including endpoints utilized, control arms, risk and MRD stratification. Whereas this was not accepted for poster presentation, stay tuned for the manuscript.", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:28.000Z", "edit_history_tweet_ids": ["1599458628410675200"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458627282415616"}], "id": "1599458628410675200", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 4, "end": 16, "username": "NamSharmaMD", "id": "1131320725682434049"}], "annotations": [{"start": 73, "end": 80, "probability": 0.2693, "type": "Other", "normalized_text": "Oncology"}, {"start": 86, "end": 92, "probability": 0.3954, "type": "Other", "normalized_text": "Onclive"}, {"start": 151, "end": 155, "probability": 0.635, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 197, "end": 220, "url": "https://t.co/TUXXrgf4Xy", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}], "hashtags": [{"start": 150, "end": 156, "tag": "ASH22"}]}, "text": "3. \n@NamSharmaMD highlights the quality of content presented at Targeted Oncology and Onclive. I am meeting representatives of these organizations at #ASH22 to discuss ways to improve reporting! \n\nhttps://t.co/TUXXrgf4Xy", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458627282415616"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458626057691137"}], "id": "1599458627282415616", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 5, "end": 18, "username": "StijnHentzen", "id": "485202660"}], "urls": [{"start": 254, "end": 277, "url": "https://t.co/Ic00FzASsX", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159807.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster II Hematology D isease Topics & Pathways: clinical trials, Research, Clinical Research, Plasma Cell Disorders, Diseases, Adverse Events, Lymphoid Malignancies Stijn Hentzen, MD 1 *, Tomer Meirson 2 *, Kelly Koehn, MD 3, Aaron M Goodman 4, Rajshekhar Chakraborty, MBBS 5, Vinay Prasad 6 *, Douglas W. Sborov, MD 7 and Ghulam Rehman Mohyuddin, MD 8 1 Department of Internal Medicine, Kansas University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159807.html"}]}, "text": "2. \n\n@StijnHentzen presents the first ever detailed analysis of a cohort of oncology trials to ascertain why and how patients drop out of trials. Disease progression, death, toxicity or other reasons such as physician preference?\n\nManuscript in review.\n\nhttps://t.co/Ic00FzASsX", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458626057691137"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458624895877121"}], "id": "1599458626057691137", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 5, "end": 14, "username": "t_etekal", "id": "1002175603"}], "annotations": [{"start": 58, "end": 60, "probability": 0.5382, "type": "Other", "normalized_text": "PFS"}, {"start": 66, "end": 67, "probability": 0.4359, "type": "Other", "normalized_text": "OS"}, {"start": 72, "end": 78, "probability": 0.6338, "type": "Other", "normalized_text": "myeloma"}, {"start": 89, "end": 91, "probability": 0.577, "type": "Other", "normalized_text": "PFS"}, {"start": 116, "end": 122, "probability": 0.5194, "type": "Other", "normalized_text": "myeloma"}, {"start": 153, "end": 155, "probability": 0.6141, "type": "Other", "normalized_text": "BJH"}], "urls": [{"start": 215, "end": 238, "url": "https://t.co/HMsT1voKGs", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163855.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis", "description": "Program: Oral and Poster Abstracts Session: 902. Health Services and Quality\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Plasma Cell Disorders, patient-reported outcomes, Diseases, Lymphoid Malignancies Tommy Etekal 1 *, Kelly Koehn, MD 2, Douglas W. Sborov, MD 3, Brian McClune, DO 4 *, Vinay Prasad 5 *, Alyson Haslam 5 *, Katherine Berger 6 *, Christopher Booth, MD 7 *, Samer", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163855.html"}]}, "text": "1. \n\n@t_etekal presents our work on the surrogacy between PFS and OS in myeloma, and how PFS events are reported in myeloma trials. Paper will be out in BJH soon- will write a full thread to explain our findings. \n\nhttps://t.co/HMsT1voKGs", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458624895877121"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458623469387777"}], "id": "1599458624895877121", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 135, "end": 150, "username": "huntsmancancer", "id": "20004102"}], "annotations": [{"start": 23, "end": 27, "probability": 0.5885, "type": "Other", "normalized_text": "ASH22"}, {"start": 121, "end": 123, "probability": 0.4909, "type": "Organization", "normalized_text": "ASH"}], "hashtags": [{"start": 22, "end": 28, "tag": "ASH22"}, {"start": 128, "end": 133, "tag": "mmsm"}]}, "text": "So looking forward to #ASH22. I have had the pleasure of mentoring many trainees remotely, who are presenting posters at ASH. \n\n#mmsm \n@huntsmancancer \n\nHere is a thread of some of the work they present.\n\nAlso, if you are a trainee- my DM's are open- would love to meet you!", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:26.000Z", "edit_history_tweet_ids": ["1599458623469387777"], "author_id": "1269642863924609025", "lang": "en", "id": "1599458623469387777", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "TargetedOnc", "id": "726304448"}, {"start": 32, "end": 45, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 46, "end": 61, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 62, "end": 77, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 78, "end": 90, "username": "NamSharmaMD", "id": "1131320725682434049"}], "annotations": [{"start": 148, "end": 155, "probability": 0.4971, "type": "Other", "normalized_text": "Oncology"}, {"start": 161, "end": 167, "probability": 0.8469, "type": "Other", "normalized_text": "OncLive"}, {"start": 191, "end": 195, "probability": 0.5869, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 198, "end": 221, "url": "https://t.co/RNX51bq9kK", "expanded_url": "https://ashpublications.org/blood/article/140/Supplement%201/10835/493054/Hype-Spin-or-Accurate-Reporting-The-Quality-of", "display_url": "ashpublications.org/blood/article/\u2026", "status": 200, "title": "Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Introduction: Oncology media websites such as Oncology Live (OncLive) and Targeted Oncology (TargetedOnc) play an important role in the dissemination of oncolog", "unwound_url": "https://ashpublications.org/blood/article/140/Supplement%201/10835/493054/Hype-Spin-or-Accurate-Reporting-The-Quality-of"}], "hashtags": [{"start": 190, "end": 196, "tag": "ASH22"}]}, "text": "@TargetedOnc Here\u2019s our work by @VPrasadMDMPH @AaronGoodman33 @MyelomaAmateur @NamSharmaMD \n\ndescribing the quality of content reported on Targeted Oncology and OncLive. Check the poster at #ASH22\n\nhttps://t.co/RNX51bq9kK", "source": "Twitter Web App", "created_at": "2022-12-04T16:48:35.000Z", "edit_history_tweet_ids": ["1599445573090037760"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599445097224892418"}], "id": "1599445573090037760", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599445097224892418"}, {"entities": {"mentions": [{"start": 96, "end": 108, "username": "TargetedOnc", "id": "726304448"}], "annotations": [{"start": 186, "end": 195, "probability": 0.7822, "type": "Other", "normalized_text": "Karyopharm"}], "urls": [{"start": 217, "end": 240, "url": "https://t.co/lY1whIeggs", "expanded_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma", "display_url": "targetedonc.com/view/clinical-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=orig", "width": 480, "height": 270}, {"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma", "description": "At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.", "unwound_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma"}]}, "text": "Is it fair for us to politely ask (without disrespecting the people being interviewed) who pays @TargetedOnc for this content?\n\nIs it fair to ask them to report money they received from Karyopharm (if any) for this?\n\nhttps://t.co/lY1whIeggs", "source": "Twitter Web App", "created_at": "2022-12-04T16:46:42.000Z", "edit_history_tweet_ids": ["1599445097224892418"], "author_id": "1269642863924609025", "lang": "en", "id": "1599445097224892418", "conversation_id": "1599445097224892418"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 16, "end": 25, "username": "CoachBon", "id": "913851074"}, {"start": 241, "end": 250, "username": "CoachBon", "id": "913851074"}, {"start": 255, "end": 270, "username": "MyelomaAmateur", "id": "1302975798304014336"}]}, "text": "@MyelomaAmateur @CoachBon I also must clarify that I was not proposing clinical trial enrollment to be a passive process, and to have interpreted my original tweet as that is an unfortunate misrepresentation of my original intent. Thank you @CoachBon and @MyelomaAmateur for calling a spade a spade.", "source": "Twitter Web App", "created_at": "2022-12-04T16:41:31.000Z", "edit_history_tweet_ids": ["1599443794654814209"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599440298840444928"}], "id": "1599443794654814209", "in_reply_to_user_id": "1302975798304014336", "conversation_id": "1599057168103538690"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "KFHemeOnc", "id": "1396562477954093057"}, {"start": 11, "end": 20, "username": "AdiG1993", "id": "1343430777321582593"}, {"start": 21, "end": 33, "username": "nihardesai7", "id": "75550503"}, {"start": 34, "end": 49, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@KFHemeOnc @AdiG1993 @nihardesai7 @AaronGoodman33 You are very kind- thank you!", "source": "Twitter Web App", "created_at": "2022-12-04T13:45:38.000Z", "edit_history_tweet_ids": ["1599399530918998018"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599157691615584257"}], "id": "1599399530918998018", "in_reply_to_user_id": "1396562477954093057", "conversation_id": "1599072194914848773"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 67, "end": 73, "probability": 0.9234, "type": "Other", "normalized_text": "twitter"}, {"start": 163, "end": 172, "probability": 0.8582, "type": "Other", "normalized_text": "belantamab"}, {"start": 193, "end": 199, "probability": 0.8067, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@HadidiSamer I think nuance will be lost describing the process on twitter unfortunately. It will be tough. \n\nI was never able to successfully consent anybody for belantamab in newly diagnosed myeloma either. \ud83d\ude41", "source": "Twitter Web App", "created_at": "2022-12-03T15:42:56.000Z", "edit_history_tweet_ids": ["1599066663718359040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599065779403563008"}], "id": "1599066663718359040", "in_reply_to_user_id": "774267564", "conversation_id": "1599057168103538690"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "text": "@GuiperiniMD Appreciate your input and sharing that. I don\u2019t think you are \u201ccorrecting\u201d something wrong I have said, but you context is helpful.", "source": "Twitter Web App", "created_at": "2022-12-03T15:29:28.000Z", "edit_history_tweet_ids": ["1599063273055604736"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599062642412306434"}], "id": "1599063273055604736", "in_reply_to_user_id": "1294745239656202240", "conversation_id": "1599057168103538690"}, {"text": "Those with intermediate risk smoldering myeloma according to 2/20/20 have a 18% chance of progression at 2 years.\n\nShould they be enrolled in a single arm small (n=15) trial of a drug with a much higher likelihood of severe toxicity (relative to risk of progression)?\n\n#mmsm https://t.co/F51Xc7ZuI3", "source": "Twitter Web App", "entities": {"annotations": [{"start": 40, "end": 46, "probability": 0.7777, "type": "Other", "normalized_text": "myeloma"}, {"start": 270, "end": 273, "probability": 0.5998, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 275, "end": 298, "url": "https://t.co/F51Xc7ZuI3", "expanded_url": "https://twitter.com/HadidiSamer/status/1599042085541142528", "display_url": "twitter.com/HadidiSamer/st\u2026"}], "hashtags": [{"start": 269, "end": 274, "tag": "mmsm"}]}, "created_at": "2022-12-03T15:05:12.000Z", "edit_history_tweet_ids": ["1599057168103538690"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599042085541142528"}], "id": "1599057168103538690", "conversation_id": "1599057168103538690"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 69, "end": 75, "probability": 0.6654, "type": "Other", "normalized_text": "myeloma"}, {"start": 87, "end": 95, "probability": 0.7154, "type": "Other", "normalized_text": "Selinexor"}, {"start": 133, "end": 135, "probability": 0.5519, "type": "Other", "normalized_text": "SMM"}]}, "text": "RT @HadidiSamer: Another day, another single arm study in smoldering myeloma. Now with Selinexor with extension to intermediate risk SMM\nWh\u2026", "source": "Twitter Web App", "created_at": "2022-12-03T14:09:16.000Z", "edit_history_tweet_ids": ["1599043092245778434"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1599042085541142528"}], "id": "1599043092245778434", "conversation_id": "1599043092245778434"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "ClayReedMD", "id": "1106254878387642368"}, {"start": 12, "end": 23, "username": "JackWestMD", "id": "28943421"}, {"start": 24, "end": 39, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 180, "end": 192, "username": "oncology_bg", "id": "3511138520"}]}, "text": "@ClayReedMD @JackWestMD @AaronGoodman33 You\u2019re very kind. Sounds hard to believe but I try to not get embroiled in too much controversy here.\n\nTo answer your question- Foremost is @oncology_bg. Must follow.", "source": "Twitter Web App", "created_at": "2022-12-03T03:02:21.000Z", "edit_history_tweet_ids": ["1598875257494179841"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598711446094987267"}], "id": "1598875257494179841", "in_reply_to_user_id": "1106254878387642368", "conversation_id": "1598711446094987267"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "MorieGertz", "id": "1316325128"}], "annotations": [{"start": 21, "end": 24, "probability": 0.5687, "type": "Other", "normalized_text": "FLCr"}, {"start": 43, "end": 53, "probability": 0.5845, "type": "Other", "normalized_text": "proteinuria"}, {"start": 74, "end": 80, "probability": 0.4691, "type": "Other", "normalized_text": "myeloma"}]}, "text": "RT @MorieGertz: Note FLCr&gt;100 even with proteinuria had median time to myeloma of over 3 years. How is this a myeloma defining event where\u2026", "source": "Twitter Web App", "created_at": "2022-12-03T00:02:36.000Z", "edit_history_tweet_ids": ["1598830022315642880"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1563324275536236544"}], "id": "1598830022315642880", "conversation_id": "1598830022315642880"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@AaronGoodman33 What is the number needed to treat to prevent one fracture (or kidney injury that does not reverse)?\n\nWould be interested to know, just not known from data.", "source": "Twitter Web App", "created_at": "2022-12-02T23:56:31.000Z", "edit_history_tweet_ids": ["1598828488697708544"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598826846082121728"}], "id": "1598828488697708544", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1598826846082121728"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "CyclingDoctor", "id": "23036480"}, {"start": 107, "end": 122, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 123, "end": 132, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 64, "end": 74, "probability": 0.669, "type": "Other", "normalized_text": "ASCO Survey"}]}, "text": "RT @CyclingDoctor: Sobering (but not surprising) results of the ASCO Survey regarding prior authorization.\n@AaronGoodman33 @ManniMD1 @Rahul\u2026", "source": "Twitter Web App", "created_at": "2022-12-02T23:51:08.000Z", "edit_history_tweet_ids": ["1598827134814130176"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1598821507920076800"}], "id": "1598827134814130176", "conversation_id": "1598827134814130176"}, {"entities": {"mentions": [{"start": 0, "end": 6, "username": "Optum", "id": "318007077"}]}, "text": "@Optum It\u2019s an inconvenience and harm to our patients foremost. I will DM details", "source": "Twitter Web App", "created_at": "2022-12-02T22:51:24.000Z", "edit_history_tweet_ids": ["1598812104190218241"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598811501393068033"}], "id": "1598812104190218241", "in_reply_to_user_id": "318007077", "conversation_id": "1598810402946961409"}, {"entities": {"mentions": [{"start": 48, "end": 54, "username": "Optum", "id": "318007077"}, {"start": 174, "end": 189, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "Why does the only person available to handle my @Optum peer to peer (a nurse case manager) get to leave for the weekend at 3:40 pm? \n\nWhat a shameful disgrace of a system \ud83d\udc94 \n@AaronGoodman33", "source": "Twitter Web App", "created_at": "2022-12-02T22:44:39.000Z", "edit_history_tweet_ids": ["1598810402946961409"], "author_id": "1269642863924609025", "lang": "en", "id": "1598810402946961409", "conversation_id": "1598810402946961409"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "AfafOsman7", "id": "1024366977425526784"}, {"start": 12, "end": 26, "username": "BloodAdvances", "id": "732570175162179585"}]}, "text": "@AfafOsman7 @BloodAdvances Congrats Afaf!", "source": "Twitter Web App", "created_at": "2022-12-02T04:30:02.000Z", "edit_history_tweet_ids": ["1598534933919563777"], "author_id": "1269642863924609025", "lang": "ca", "referenced_tweets": [{"type": "replied_to", "id": "1598345125419044864"}], "id": "1598534933919563777", "in_reply_to_user_id": "1024366977425526784", "conversation_id": "1598345125419044864"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "AfafOsman7", "id": "1024366977425526784"}, {"start": 70, "end": 84, "username": "BloodAdvances", "id": "732570175162179585"}], "annotations": [{"start": 132, "end": 137, "probability": 0.453, "type": "Other", "normalized_text": "clonal"}]}, "text": "RT @AfafOsman7: Hips don't lie: my fellowship project found a home at @BloodAdvances. I'm excited about the questions we raised: Is clonal\u2026", "source": "Twitter Web App", "created_at": "2022-12-02T04:29:39.000Z", "edit_history_tweet_ids": ["1598534836960264192"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1598345125419044864"}], "id": "1598534836960264192", "conversation_id": "1598534836960264192"}, {"entities": {"mentions": [{"start": 0, "end": 16, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}], "annotations": [{"start": 57, "end": 59, "probability": 0.635, "type": "Organization", "normalized_text": "ASH"}]}, "text": "@BrunoPaiva_UNAV Look forward to discussing in person at ASH!", "source": "Twitter Web App", "created_at": "2022-12-01T05:30:31.000Z", "edit_history_tweet_ids": ["1598187768181841921"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598181778006585345"}], "id": "1598187768181841921", "in_reply_to_user_id": "1335161063382376448", "conversation_id": "1598124890405883904"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "CoachBon", "id": "913851074"}, {"start": 10, "end": 22, "username": "TMSchmidtMD", "id": "1022478983760359424"}, {"start": 23, "end": 39, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 40, "end": 53, "username": "MeeraMohanMD", "id": "1087342265645875200"}, {"start": 54, "end": 66, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 76, "end": 81, "probability": 0.6437, "type": "Other", "normalized_text": "Bonnie"}, {"start": 204, "end": 206, "probability": 0.8374, "type": "Other", "normalized_text": "PDF"}]}, "text": "@CoachBon @TMSchmidtMD @RahulBanerjeeMD @MeeraMohanMD @HadidiSamer Hi Coach Bonnie- the entire paper is covered in a snapshot picture of the first tweet of this thread. Please DM me and I can email you a PDF too.", "source": "Twitter Web App", "created_at": "2022-12-01T02:17:51.000Z", "edit_history_tweet_ids": ["1598139283746930690"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598138965009502208"}], "id": "1598139283746930690", "in_reply_to_user_id": "913851074", "conversation_id": "1403346298284163075"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 92, "end": 115, "url": "https://t.co/SERddRh414", "expanded_url": "https://twitter.com/ManniMD1/status/1403346298284163075?s=20&t=M3MRqcc5IxziLPD6gcfNQQ", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "@AaronGoodman33 As you and I pointed out in our paper (here\u2019s the thread for that paper):\n\n https://t.co/SERddRh414", "source": "Twitter Web App", "created_at": "2022-12-01T02:04:41.000Z", "edit_history_tweet_ids": ["1598135969617960960"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1403346298284163075"}, {"type": "replied_to", "id": "1598135519157723137"}], "id": "1598135969617960960", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1598134143954857984"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@AaronGoodman33 I do think there is merit to 1-2 such studies and I commend this group for trying this intervention. Worth seeing if patients were cured by this approach. However why would studying a different 3 or 4 drug combo (as is done in many single-arm studies) lead to different results?", "source": "Twitter Web App", "created_at": "2022-12-01T02:02:09.000Z", "edit_history_tweet_ids": ["1598135332691595264"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598134143954857984"}], "id": "1598135332691595264", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1598134143954857984"}, {"text": "Link to abstract:\nhttps://t.co/2x1ves2uLo", "source": "Twitter Web App", "entities": {"urls": [{"start": 18, "end": 41, "url": "https://t.co/2x1ves2uLo", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}]}, "created_at": "2022-12-01T01:21:02.000Z", "edit_history_tweet_ids": ["1598124983804624898"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598124890405883904"}], "id": "1598124983804624898", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1598124890405883904"}, {"text": "Amongst most profound observations from #ASH22 \n\nIf sustained MRD neg is best surrogate for cure, note that aggressive attempt to \"cure\" smoldering MM using KRD&gt;trans&gt;maintenance led to only 23% sustained MRD neg.\n\nImmense implications for smoldering MM/early intervention.\n\n#mmsm https://t.co/EK29OHpfAG", "source": "Twitter Web App", "entities": {"annotations": [{"start": 41, "end": 45, "probability": 0.6528, "type": "Other", "normalized_text": "ASH22"}, {"start": 62, "end": 64, "probability": 0.6256, "type": "Other", "normalized_text": "MRD"}, {"start": 157, "end": 159, "probability": 0.4539, "type": "Other", "normalized_text": "KRD"}, {"start": 211, "end": 213, "probability": 0.4711, "type": "Other", "normalized_text": "MRD"}, {"start": 282, "end": 285, "probability": 0.505, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 287, "end": 310, "url": "https://t.co/EK29OHpfAG", "expanded_url": "https://twitter.com/ManniMD1/status/1598124890405883904/photo/1", "display_url": "pic.twitter.com/EK29OHpfAG", "media_key": "3_1598124526486769666"}], "hashtags": [{"start": 40, "end": 46, "tag": "ASH22"}, {"start": 281, "end": 286, "tag": "mmsm"}]}, "created_at": "2022-12-01T01:20:40.000Z", "edit_history_tweet_ids": ["1598124890405883904"], "author_id": "1269642863924609025", "lang": "en", "id": "1598124890405883904", "conversation_id": "1598124890405883904"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "HemeOncBuddy", "id": "939599146608152576"}], "annotations": [{"start": 64, "end": 67, "probability": 0.7687, "type": "Other", "normalized_text": "Veli"}]}, "text": "@HemeOncBuddy Thanks as always for your kind words and support, Veli!", "source": "Twitter Web App", "created_at": "2022-11-28T17:37:39.000Z", "edit_history_tweet_ids": ["1597283595579949056"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596132927179722753"}], "id": "1597283595579949056", "in_reply_to_user_id": "939599146608152576", "conversation_id": "1596132927179722753"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "amirsali101", "id": "951231260306718720"}], "annotations": [{"start": 75, "end": 77, "probability": 0.3565, "type": "Organization", "normalized_text": "ASH"}]}, "text": "@amirsali101 Thanks for reading and sharing. Hope to meet you in person at ASH", "source": "Twitter for iPhone", "created_at": "2022-11-28T17:30:19.000Z", "edit_history_tweet_ids": ["1597281747640938497"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1597249248021852160"}], "id": "1597281747640938497", "in_reply_to_user_id": "951231260306718720", "conversation_id": "1597249248021852160"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "amirsali101", "id": "951231260306718720"}, {"start": 45, "end": 54, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 56, "end": 59, "probability": 0.4606, "type": "Other", "normalized_text": "mmsm"}], "hashtags": [{"start": 55, "end": 60, "tag": "mmsm"}]}, "text": "RT @amirsali101: Great critical appraisal by @ManniMD1\n#mmsm", "source": "Twitter for iPhone", "created_at": "2022-11-28T17:30:08.000Z", "edit_history_tweet_ids": ["1597281700668919808"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1597249248021852160"}], "id": "1597281700668919808", "conversation_id": "1597281700668919808"}, {"text": "This has bothered us for a long time- now we have data to prove it:\n\nhttps://t.co/TUXXrgf4Xy\n\nPatients and health care professionals deserve honest, unbiased reporting! https://t.co/56kwy3t1AT", "source": "Twitter for iPhone", "entities": {"urls": [{"start": 69, "end": 92, "url": "https://t.co/TUXXrgf4Xy", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}, {"start": 169, "end": 192, "url": "https://t.co/56kwy3t1AT", "expanded_url": "https://twitter.com/AaronGoodman33/status/1596993595986542592", "display_url": "twitter.com/AaronGoodman33\u2026"}]}, "created_at": "2022-11-27T23:13:51.000Z", "edit_history_tweet_ids": ["1597005812949725189"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596993595986542592"}], "id": "1597005812949725189", "conversation_id": "1597005812949725189"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 88, "end": 97, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 98, "end": 113, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 41, "end": 47, "probability": 0.7083, "type": "Other", "normalized_text": "OncLive"}, {"start": 52, "end": 54, "probability": 0.5043, "type": "Organization", "normalized_text": "ASH"}], "urls": [{"start": 115, "end": 138, "url": "https://t.co/Ts55UVUijG", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}]}, "text": "RT @VPrasadMDMPH: This is why we studied OncLive at ASH &amp; found it loaded with bias\n@ManniMD1 @AaronGoodman33 \nhttps://t.co/Ts55UVUijG\n\nLoo\u2026", "source": "Twitter for iPhone", "created_at": "2022-11-27T22:14:48.000Z", "edit_history_tweet_ids": ["1596990951376924677"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596988450385063937"}], "id": "1596990951376924677", "conversation_id": "1596990951376924677"}, {"entities": {"mentions": [{"start": 33, "end": 45, "username": "Eddie_Cliff", "id": "74081884"}], "urls": [{"start": 70, "end": 93, "url": "https://t.co/ojBa57xuoU", "expanded_url": "https://twitter.com/Eddie_Cliff/status/1596684108184408066", "display_url": "twitter.com/Eddie_Cliff/st\u2026"}]}, "text": "A thoughtful thread by my friend @Eddie_Cliff on immortal time bias\ud83d\udc47\ud83c\udffe https://t.co/ojBa57xuoU", "source": "Twitter for iPhone", "created_at": "2022-11-27T17:05:46.000Z", "edit_history_tweet_ids": ["1596913182978629632"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596684108184408066"}], "id": "1596913182978629632", "conversation_id": "1596913182978629632"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 27, "username": "DrRakeshPopat", "id": "1202400046760841218"}, {"start": 28, "end": 42, "username": "DrSanjayPopat", "id": "780503912260468736"}]}, "text": "@chadinabhan @DrRakeshPopat @DrSanjayPopat I\u2019m excited to hear this!", "source": "Twitter for iPhone", "created_at": "2022-11-27T16:52:15.000Z", "edit_history_tweet_ids": ["1596909778659201024"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596864022548185089"}], "id": "1596909778659201024", "in_reply_to_user_id": "2212735524", "conversation_id": "1596864022548185089"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 16, "end": 30, "username": "TheLancetHaem", "id": "2596297298"}, {"start": 31, "end": 46, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 47, "end": 55, "username": "OncLive", "id": "43051682"}], "annotations": [{"start": 65, "end": 71, "probability": 0.7946, "type": "Other", "normalized_text": "twitter"}]}, "text": "@MyelomaAmateur @TheLancetHaem @AaronGoodman33 @OncLive You make twitter worth it! Look forward to so many ongoing collabs!", "source": "Twitter for iPhone", "created_at": "2022-11-27T14:44:11.000Z", "edit_history_tweet_ids": ["1596877551137624066"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596877141836435456"}], "id": "1596877551137624066", "in_reply_to_user_id": "1302975798304014336", "conversation_id": "1596877141836435456"}, {"entities": {"mentions": [{"start": 3, "end": 18, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 39, "end": 48, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "RT @MyelomaAmateur: I'm so grateful to @ManniMD1 for his v. patient mentorship &amp; his skilled guidance in nurturing distraught rage tweets i\u2026", "source": "Twitter for iPhone", "created_at": "2022-11-27T14:43:17.000Z", "edit_history_tweet_ids": ["1596877325705965568"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596877141836435456"}], "id": "1596877325705965568", "conversation_id": "1596877325705965568"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 67, "end": 76, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 83, "end": 98, "username": "AaronGoodman33", "id": "854692626015993857"}], "hashtags": [{"start": 122, "end": 128, "tag": "ASH22"}]}, "text": "RT @chadinabhan: Listen to these two who have never had a haircut. @ManniMD1 &amp; @AaronGoodman33 describe their planned #ASH22 @ASH_hematolog\u2026", "source": "Twitter for iPhone", "created_at": "2022-11-27T01:27:19.000Z", "edit_history_tweet_ids": ["1596677013384962053"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596628186150096896"}], "id": "1596677013384962053", "conversation_id": "1596677013384962053"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "geekbabe", "id": "18792477"}, {"start": 10, "end": 22, "username": "chadinabhan", "id": "2212735524"}, {"start": 23, "end": 38, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 39, "end": 54, "username": "ASH_hematology", "id": "84072624"}, {"start": 55, "end": 63, "username": "OncLive", "id": "43051682"}]}, "text": "@geekbabe @chadinabhan @AaronGoodman33 @ASH_hematology @OncLive Thank you for sharing your story with us. There\u2019s so much nuance that is lost in oncology news media reporting. Our goal is for more truthful discourse so that patients aren\u2019t misled. There are some truly transformative developments but many marginal ones too.", "source": "Twitter for iPhone", "created_at": "2022-11-26T21:09:59.000Z", "edit_history_tweet_ids": ["1596612254312857601"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596608402473750529"}], "id": "1596612254312857601", "in_reply_to_user_id": "18792477", "conversation_id": "1596544838874566658"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 41, "username": "chadinabhan", "id": "2212735524"}, {"start": 42, "end": 57, "username": "ASH_hematology", "id": "84072624"}, {"start": 58, "end": 66, "username": "OncLive", "id": "43051682"}]}, "text": "@nihardesai7 @AaronGoodman33 @chadinabhan @ASH_hematology @OncLive Thanks bro, it\u2019s a desi thing. Our desi hair always wins \ud83d\ude1c", "source": "Twitter for iPhone", "created_at": "2022-11-26T18:43:53.000Z", "edit_history_tweet_ids": ["1596575487794434049"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596575339895214080"}], "id": "1596575487794434049", "in_reply_to_user_id": "75550503", "conversation_id": "1596544838874566658"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 73, "end": 75, "probability": 0.6576, "type": "Other", "normalized_text": "ASH"}]}, "text": "RT @HadidiSamer: Check out work out that will be highlighted at the 2022 ASH Poster Walk on Diversity,Equity,and Inclusion\nIt covers a very\u2026", "source": "Twitter Web App", "created_at": "2022-11-26T17:53:31.000Z", "edit_history_tweet_ids": ["1596562811559108608"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596561188954943488"}], "id": "1596562811559108608", "conversation_id": "1596562811559108608"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 55, "end": 64, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 71, "end": 86, "username": "AaronGoodman33", "id": "854692626015993857"}], "hashtags": [{"start": 95, "end": 116, "tag": "HealthcareUnfiltered"}]}, "text": "RT @chadinabhan: Zero editing.\nZero filter.\n\nThese two @ManniMD1 &amp; @AaronGoodman33 come on #HealthcareUnfiltered for a 10 mins blitz talkin\u2026", "source": "Twitter Web App", "created_at": "2022-11-26T16:48:09.000Z", "edit_history_tweet_ids": ["1596546362010656768"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596544838874566658"}], "id": "1596546362010656768", "conversation_id": "1596546362010656768"}, {"entities": {"mentions": [{"start": 19, "end": 34, "username": "MyelomaAmateur", "id": "1302975798304014336"}, {"start": 121, "end": 135, "username": "TheLancetHaem", "id": "2596297298"}], "annotations": [{"start": 196, "end": 198, "probability": 0.4827, "type": "Other", "normalized_text": "PFS"}], "urls": [{"start": 218, "end": 241, "url": "https://t.co/j2mmSrPPL5", "expanded_url": "https://www.thelancet.com/pdfs/journals/lanhae/PIIS2352-3026(22)00006-0.pdf", "display_url": "thelancet.com/pdfs/journals/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1596546091037896704/colWqmwD?format=jpg&name=orig", "width": 181, "height": 272}, {"url": "https://pbs.twimg.com/news_img/1596546091037896704/colWqmwD?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Reporting of trials with possible detrimental overall survival: a patient advocate perspective", "description": "On Oct 22, 2021, melflufen, a novel peptide\u2013drug conjugate intended for use in relapsed or refractory multiple myeloma, was withdrawn from the US market by the pharmaceutical company that developed it, Oncopeptides, on the basis of possible detrimental overall survival in the group that received melflufen in its confirmatory OCEAN trial. Only a month earlier\u2014and despite an existing US Food and Drug Administration hold due to an increased number of patient deaths in the melflufen group\u2014the same trial had received positive coverage when it was presented at the International Myeloma Workshop (IMW; Sept 8\u201311, 2021, in Vienna, Austria).", "unwound_url": "https://www.thelancet.com/pdfs/journals/lanhae/PIIS2352-3026(22)00006-0.pdf"}], "hashtags": [{"start": 243, "end": 248, "tag": "mmsm"}]}, "text": "I owe gratitude to @MyelomaAmateur, a patient advocate who inspired us to do this.\n\nI published this article with her in @TheLancetHaem on how oncology news media reported on a drug that improved PFS but worsened OS:\n\nhttps://t.co/j2mmSrPPL5\n\n#mmsm", "source": "Twitter Web App", "created_at": "2022-11-26T16:47:04.000Z", "edit_history_tweet_ids": ["1596546087749586944"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596545686903873536"}], "id": "1596546087749586944", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1596545686903873536"}, {"entities": {"mentions": [{"start": 154, "end": 166, "username": "NamSharmaMD", "id": "1131320725682434049"}], "annotations": [{"start": 191, "end": 195, "probability": 0.6297, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/TUXXrgex80", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}, {"start": 274, "end": 297, "url": "https://t.co/s9SQO4i2j8", "expanded_url": "https://twitter.com/chadinabhan/status/1596544838874566658", "display_url": "twitter.com/chadinabhan/st\u2026"}], "hashtags": [{"start": 20, "end": 41, "tag": "HealthcareUnfiltered"}, {"start": 190, "end": 196, "tag": "ASH22"}]}, "text": "A pleasure being on #HealthcareUnfiltered to discuss the problem of hype in oncology news media reporting. Potential solutions discussed, look forward to @NamSharmaMD presenting our work at #ASH22, and sharing manuscript once accepted.\n\nOur poster:\n\nhttps://t.co/TUXXrgex80 https://t.co/s9SQO4i2j8", "source": "Twitter Web App", "created_at": "2022-11-26T16:45:28.000Z", "edit_history_tweet_ids": ["1596545686903873536"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596544838874566658"}], "id": "1596545686903873536", "conversation_id": "1596545686903873536"}], "includes": {"users": [{"id": "1269642863924609025", "name": "Manni Mohyuddin", "username": "ManniMD1"}, {"id": "2212735524", "name": "chadi nabhan MD, MBA, FACP", "username": "chadinabhan"}, {"id": "872983600416862208", "name": "Ben Derman", "username": "bdermanmd"}, {"id": "898851661", "name": "Chris Strouse", "username": "strouse_chris"}, {"id": "1541226866870292480", "name": "Konstantinos Lontos", "username": "KonLontos"}, {"id": "1153334819310505985", "name": "Amaris Balitsky", "username": "Balitsky_HemeMD"}, {"id": "75550503", "name": "\ud835\udde1\ud835\uddf6\ud835\uddf5\ud835\uddee\ud835\uddff \ud835\uddd7\ud835\uddf2\ud835\ude00\ud835\uddee\ud835\uddf6", "username": "nihardesai7"}, {"id": "990578290690797570", "name": "Felipe Pe\u00f1a Mu\u00f1oz", "username": "HematoRules"}, {"id": "913851074", "name": "Coach Bonnie", "username": "CoachBon"}, {"id": "1205790868730462213", "name": "Rita Assi", "username": "RitaAssi4"}, {"id": "561122329", "name": "Ankit kansagra", "username": "kansagraMD"}, {"id": "74081884", "name": "Eddie Cliff", "username": "Eddie_Cliff"}, {"id": "1105483475296178176", "name": "\ud83e\ude78Matthew Brunner\ud83e\ude78", "username": "mattjbrunner"}, {"id": "964268621655695360", "name": "Bijoy Telivala", "username": "BijoyTelivala"}, {"id": "4067920889", "name": "Jose Sandoval S, MD FACP \ud83c\udde8\ud83c\uddf4\ud83c\udde8\ud83c\uddf4", "username": "HemSandoval"}, {"id": "626650397", "name": "Michael Slade, MD", "username": "MichaelJSlade"}, {"id": "419595308", "name": "Hira Mian", "username": "HiraSMian"}, {"id": "1163750299", "name": "Artur Jurczyszyn", "username": "AJurczyszyn"}, {"id": "3078258341", "name": "Sigurdur Kristinsson", "username": "sykristinsson"}, {"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}, {"id": "1336329089100046339", "name": "RahulDoc", "username": "RahulDoc2"}, {"id": "140966169", "name": "Raj Chakraborty", "username": "rajshekharucms"}, {"id": "284694610", "name": "Kevin Rakszawski, MD", "username": "KRakszawski"}, {"id": "24261916", "name": "Vincent Rajkumar", "username": "VincentRK"}, {"id": "327808606", "name": "Infection Prevention RN", "username": "RnInfection"}, {"id": "1302975798304014336", "name": "Kate", "username": "MyelomaAmateur"}, {"id": "1396562477954093057", "name": "Kiavasch Farid", "username": "KFHemeOnc"}, {"id": "774267564", "name": "Samer Al Hadidi, MD,MS,FACP", "username": "HadidiSamer"}, {"id": "1294745239656202240", "name": "Guilherme Perini, MD", "username": "GuiperiniMD"}, {"id": "1106254878387642368", "name": "Clay Reed, MD", "username": "ClayReedMD"}, {"id": "318007077", "name": "Optum", "username": "Optum"}, {"id": "1024366977425526784", "name": "Afaf Osman, MD", "username": "AfafOsman7"}, {"id": "1335161063382376448", "name": "Bruno Paiva", "username": "BrunoPaiva_UNAV"}, {"id": "939599146608152576", "name": "Veli Bakalov, MD", "username": "HemeOncBuddy"}, {"id": "951231260306718720", "name": "Amir Ali, PharmD, BCOP", "username": "amirsali101"}, {"id": "18792477", "name": "Jean Parks", "username": "geekbabe"}], "tweets": [{"entities": {"mentions": [{"start": 14, "end": 29, "username": "ASH_hematology", "id": "84072624"}, {"start": 42, "end": 57, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 64, "end": 74, "username": "VincentRK", "id": "24261916"}], "urls": [{"start": 163, "end": 186, "url": "https://t.co/meTuqRdRda", "expanded_url": "https://twitter.com/chadinabhan/status/1601400573555019776/photo/1", "display_url": "pic.twitter.com/meTuqRdRda", "media_key": "3_1601400455678001152"}], "hashtags": [{"start": 30, "end": 36, "tag": "ASH22"}]}, "text": "Right here at @ASH_hematology #ASH22 with @AaronGoodman33 &amp; @VincentRK discussing science, mentorship, and music. \n\nGreat fellowship mentorship program today. https://t.co/meTuqRdRda", "source": "Twitter for iPhone", "created_at": "2022-12-10T02:17:03.000Z", "edit_history_tweet_ids": ["1601400573555019776"], "author_id": "2212735524", "lang": "en", "id": "1601400573555019776", "conversation_id": "1601400573555019776"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@ManniMD1 This probably reflects the sun extent of the challenges i\u2019m getting a patient to transplant who is more frail, but I think we need to look at who actually moved forward with ASCT.", "source": "Twitter for iPhone", "created_at": "2022-12-10T00:11:56.000Z", "edit_history_tweet_ids": ["1601369086243786753"], "author_id": "872983600416862208", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601368729635655681"}], "id": "1601369086243786753", "in_reply_to_user_id": "872983600416862208", "conversation_id": "1601305074629648385"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "nihardesai7", "id": "75550503"}]}, "text": "@AaronGoodman33 @nihardesai7 Do you find the IMWG frailty score clinically useful for this? I haven\u2019t been able to convince myself to change course when it disagrees with my gestalt yet", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:26:12.000Z", "edit_history_tweet_ids": ["1601342476056670208"], "author_id": "898851661", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601337861814759424"}], "id": "1601342476056670208", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1601335757213696003"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@AaronGoodman33 let\u2019s wait the full data because often that means that you don\u2019t need to do it upfront but it is useful at some point down the road", "source": "Twitter Web App", "created_at": "2022-12-09T22:15:33.000Z", "edit_history_tweet_ids": ["1601339797598965760"], "author_id": "1541226866870292480", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601335757213696003"}], "id": "1601339797598965760", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1601335757213696003"}, {"entities": {"mentions": [{"start": 22, "end": 32, "username": "HiraSMian", "id": "419595308"}], "annotations": [{"start": 39, "end": 41, "probability": 0.4616, "type": "Organization", "normalized_text": "nti"}, {"start": 71, "end": 77, "probability": 0.4201, "type": "Other", "normalized_text": "text #A"}, {"start": 81, "end": 89, "probability": 0.5605, "type": "Other", "normalized_text": "022, #CAR"}], "urls": [{"start": 97, "end": 120, "url": "https://t.co/RBtcWqowPD", "expanded_url": "https://twitter.com/Balitsky_HemeMD/status/1601304691685691392/photo/1", "display_url": "pic.twitter.com/RBtcWqowPD", "media_key": "3_1601304681250263043"}], "hashtags": [{"start": 76, "end": 84, "tag": "ASH2022"}, {"start": 86, "end": 96, "tag": "CAREatASH"}]}, "text": "\u2066superstar colleague \u2066@HiraSMian\u2069 presenting ASH highlights in a \ud83c\udde8\ud83c\udde6 context #ASH2022, #CAREatASH https://t.co/RBtcWqowPD", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:56:03.000Z", "edit_history_tweet_ids": ["1601304691685691392"], "author_id": "1153334819310505985", "lang": "en", "id": "1601304691685691392", "conversation_id": "1601304691685691392"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@AaronGoodman33 Why wasn't the induction with dara- len-dex??", "source": "Twitter for Android", "created_at": "2022-12-09T22:12:22.000Z", "edit_history_tweet_ids": ["1601338994280710144"], "author_id": "75550503", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1601337861814759424"}], "id": "1601338994280710144", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1601335757213696003"}, {"text": "Interesting! Why not to use DaraLenDex as 1st line treatment in these patients? #ASH22 https://t.co/4wzq2v6umf", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 28, "end": 37, "probability": 0.5548, "type": "Other", "normalized_text": "DaraLenDex"}, {"start": 81, "end": 85, "probability": 0.6341, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 87, "end": 110, "url": "https://t.co/4wzq2v6umf", "expanded_url": "https://twitter.com/mannimd1/status/1601305074629648385", "display_url": "twitter.com/mannimd1/statu\u2026"}], "hashtags": [{"start": 80, "end": 86, "tag": "ASH22"}]}, "created_at": "2022-12-09T22:01:42.000Z", "edit_history_tweet_ids": ["1601336310186520579"], "author_id": "990578290690797570", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601305074629648385"}], "id": "1601336310186520579", "conversation_id": "1601336310186520579"}, {"entities": {"mentions": [{"start": 243, "end": 257, "username": "ShakiraG_MBBS", "id": "1194921398059311104"}, {"start": 258, "end": 268, "username": "stuchman1", "id": "487185530"}], "annotations": [{"start": 21, "end": 24, "probability": 0.5786, "type": "Other", "normalized_text": "mmsm"}, {"start": 49, "end": 53, "probability": 0.7328, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 218, "end": 241, "url": "https://t.co/QJR4sU8GvB", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167763.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: \"If You Don\u2019t Trust Your Doctor That Much...You\u2019d Feel Less Confident Doing a Research Study\": Factors Influencing Black Patient Participation in Hematology Trials", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 905. Outcomes Research\u2014Lymphoid Ma lignancies: Patient Representation and Equity in Hematologic Malignancies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) Shakira J. Grant, MBBS 1,2, Milenka Jean-Baptiste, MPH 3 *, Mykela Moore, BA 3 *, Jiona Mills, BSPH 3 *, Lauren Bates, MA 4 *, Sascha A. Tuchman, MD, MHS 1,2 and Paul Mihas, MA 5 * 1 Lineberger Comprehensive Cancer", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167763.html"}, {"start": 269, "end": 292, "url": "https://t.co/aw10T0N8qj", "expanded_url": "https://twitter.com/ManniMD1/status/1600482351523409920/photo/1", "display_url": "pic.twitter.com/aw10T0N8qj", "media_key": "3_1600482116734636032"}], "hashtags": [{"start": 20, "end": 25, "tag": "mmsm"}, {"start": 48, "end": 54, "tag": "ASH22"}]}, "text": "Perhaps my favorite #mmsm disparity research at #ASH22.\n\nRather than comparing outcomes between races in another dataset, or describing low enrollment in trials, this study helps us understand the \u201cwhy\u201d of the story.\n\nhttps://t.co/QJR4sU8GvB\n\n@ShakiraG_MBBS @stuchman1 https://t.co/aw10T0N8qj", "source": "Twitter Web App", "created_at": "2022-12-07T13:28:22.000Z", "edit_history_tweet_ids": ["1600482351523409920"], "author_id": "1269642863924609025", "lang": "en", "id": "1600482351523409920", "conversation_id": "1600482351523409920"}, {"text": "\u2b50\ufe0fPractice changing abstract\n\n\u2b50\ufe0fMel140 fails to beat len/dex in 60-75 year olds\n\nThis combined with lack of OS benefit to date in DETERMINATION/IFM 2009 has considerably lessened enthusiasm to transpl (esp mel140) standard risk #mmsm above age 70.\n\n#ASH22\nhttps://t.co/9NykX99A65", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 130, "end": 142, "probability": 0.5258, "type": "Other", "normalized_text": "DETERMINATION"}, {"start": 144, "end": 146, "probability": 0.7035, "type": "Other", "normalized_text": "IFM"}], "urls": [{"start": 256, "end": 279, "url": "https://t.co/9NykX99A65", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed M", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Research, clinical trials, adult, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Study Population, Human 1 Clinic of Hematology, Oncology and Stem Cell Transplantation, Muenchen Klinik Schwabing, Munich, Germany 2 Klinikum Nuernberg, Nuernberg,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html"}], "hashtags": [{"start": 228, "end": 233, "tag": "mmsm"}, {"start": 249, "end": 255, "tag": "ASH22"}]}, "created_at": "2022-12-09T19:57:35.000Z", "edit_history_tweet_ids": ["1601305074629648385"], "author_id": "1269642863924609025", "lang": "en", "id": "1601305074629648385", "conversation_id": "1601305074629648385"}, {"text": "Let\u2019s look at 2 smoldering MM trials presented #ASH22 of from different(important) angles #mmsm \ud83e\uddf5\n\nASCENT trial (US)\nGEM-CESAR trial (Europe)\n\n\u27a1\ufe0fhttps://t.co/7fggQ0DrCd\n\u27a1\ufe0f https://t.co/rqgmPbMee8\n\nTreatment drugs and duration\ud83d\udc47\n\nASCENT:Dara-KRd(2yrs)\nGEM-CESAR:KRd+auto (~3yrs) https://t.co/ikAGsUMOJo", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 113, "end": 114, "probability": 0.808, "type": "Place", "normalized_text": "US"}, {"start": 134, "end": 139, "probability": 0.8606, "type": "Place", "normalized_text": "Europe"}, {"start": 235, "end": 238, "probability": 0.381, "type": "Other", "normalized_text": "Dara"}], "urls": [{"start": 145, "end": 168, "url": "https://t.co/7fggQ0DrCd", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}, {"start": 172, "end": 195, "url": "https://t.co/rqgmPbMee8", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}, {"start": 277, "end": 300, "url": "https://t.co/ikAGsUMOJo", "expanded_url": "https://twitter.com/HadidiSamer/status/1601170628899323904/photo/1", "display_url": "pic.twitter.com/ikAGsUMOJo", "media_key": "3_1601170620187918336"}], "hashtags": [{"start": 47, "end": 53, "tag": "ASH22"}, {"start": 90, "end": 95, "tag": "mmsm"}]}, "created_at": "2022-12-09T11:03:20.000Z", "edit_history_tweet_ids": ["1601170628899323904"], "author_id": "774267564", "lang": "en", "id": "1601170628899323904", "conversation_id": "1601170628899323904"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@ManniMD1 Mind blowing...how to think about this??", "source": "Twitter Web App", "created_at": "2022-12-08T23:35:37.000Z", "edit_history_tweet_ids": ["1600997558708760576"], "author_id": "913851074", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600938853308645376"}], "id": "1600997558708760576", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 91, "end": 106, "username": "ASH_hematology", "id": "84072624"}, {"start": 109, "end": 118, "username": "n_gangat", "id": "2833103654"}, {"start": 121, "end": 130, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 133, "end": 144, "username": "mlblack1_b", "id": "1118423599"}], "annotations": [{"start": 21, "end": 25, "probability": 0.707, "type": "Other", "normalized_text": "ASH22"}, {"start": 70, "end": 82, "probability": 0.6462, "type": "Other", "normalized_text": "ASH New Daily"}], "urls": [{"start": 147, "end": 170, "url": "https://t.co/UI495cTIsx", "expanded_url": "https://ashpublications.org/ashnewsdaily/search-results?f_SemanticFilterTopics=PreviewANDASH+2022", "display_url": "ashpublications.org/ashnewsdaily/s\u2026", "status": 200, "title": "Search Results | ASH News Daily | American Society of Hematology", "description": "Would you like to receive an alert when new items match your", "unwound_url": "https://ashpublications.org/ashnewsdaily/search-results?f_SemanticFilterTopics=PreviewANDASH+2022"}], "hashtags": [{"start": 20, "end": 26, "tag": "ASH22"}]}, "text": "Getting excited for #ASH22 Check out the preview issue by our amazing ASH New Daily crew! \u2066@ASH_hematology\u2069 \u2066@n_gangat\u2069 \u2066@ManniMD1\u2069 \u2066@mlblack1_b\u2069  https://t.co/UI495cTIsx", "source": "Twitter for iPhone", "created_at": "2022-12-09T00:18:46.000Z", "edit_history_tweet_ids": ["1601008414762622977"], "author_id": "747629405225127940", "lang": "en", "id": "1601008414762622977", "conversation_id": "1601008414762622977"}, {"entities": {"mentions": [{"start": 133, "end": 144, "username": "doctorpemm", "id": "2429552622"}, {"start": 145, "end": 156, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 157, "end": 171, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}, {"start": 172, "end": 181, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 18, "end": 24, "probability": 0.6649, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 17, "end": 25, "tag": "ASH2022"}]}, "text": "Unable to attend #ASH2022 in person; but relying on some amazing tweeters to get the gist while virtually attending as much as I can\n@doctorpemm @Mohty_EBMT @Dr_AmerZeidan @ManniMD1 and many many others!", "source": "Twitter for Android", "created_at": "2022-12-09T01:44:50.000Z", "edit_history_tweet_ids": ["1601030075939311616"], "author_id": "1205790868730462213", "lang": "en", "id": "1601030075939311616", "conversation_id": "1601030075939311616"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 32, "end": 34, "probability": 0.6087, "type": "Other", "normalized_text": "MRD"}, {"start": 81, "end": 83, "probability": 0.5222, "type": "Other", "normalized_text": "MRD"}, {"start": 106, "end": 108, "probability": 0.6053, "type": "Other", "normalized_text": "SMM"}, {"start": 165, "end": 167, "probability": 0.4977, "type": "Other", "normalized_text": "MRF"}, {"start": 197, "end": 199, "probability": 0.4363, "type": "Other", "normalized_text": "KRD"}, {"start": 254, "end": 256, "probability": 0.5681, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 282, "end": 305, "url": "https://t.co/BmgDLN7aDQ", "expanded_url": "https://twitter.com/kansagraMD/status/1601013460799614976/photo/1", "display_url": "pic.twitter.com/BmgDLN7aDQ", "media_key": "3_1601013457549250561"}]}, "text": "@ManniMD1 Are we surprised that MRD rate is low ? If you look at quad therapies  MRD rates! Did we expect SMM (idk pop, but eg high risk) will have significant high MRF rates ? \n\nNot proposing for KRD/Tx/Main as Rx but realizing what shld we expect from SMM fully loaded Rx options https://t.co/BmgDLN7aDQ", "source": "Twitter for iPhone", "created_at": "2022-12-09T00:38:49.000Z", "edit_history_tweet_ids": ["1601013460799614976"], "author_id": "561122329", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600938853308645376"}], "id": "1601013460799614976", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 156, "end": 167, "username": "dgermain21", "id": "18821994"}], "annotations": [{"start": 18, "end": 26, "probability": 0.4082, "type": "Organization", "normalized_text": "Southwest"}, {"start": 99, "end": 102, "probability": 0.9496, "type": "Place", "normalized_text": "NOLA"}, {"start": 171, "end": 178, "probability": 0.9315, "type": "Place", "normalized_text": "St Louis"}], "urls": [{"start": 215, "end": 238, "url": "https://t.co/H2nCrg8tNW", "expanded_url": "https://twitter.com/Eddie_Cliff/status/1601020063590776832/photo/1", "display_url": "pic.twitter.com/H2nCrg8tNW", "media_key": "3_1601020056137355264"}], "hashtags": [{"start": 108, "end": 114, "tag": "ASH22"}]}, "text": "Survived my first Southwest airlines boarding experience (no allocated seats!) and now en route to NOLA for #ASH22 after a lovely stopover visiting the fab @dgermain21 in St Louis! See you soon fellow haem nerds \ud83e\udd73\ud83e\ude78 https://t.co/H2nCrg8tNW", "source": "Twitter for iPhone", "created_at": "2022-12-09T01:05:03.000Z", "edit_history_tweet_ids": ["1601020063590776832"], "author_id": "74081884", "lang": "en", "id": "1601020063590776832", "conversation_id": "1601020063590776832"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 145, "end": 147, "probability": 0.6193, "type": "Other", "normalized_text": "SMM"}]}, "text": "@ManniMD1 Too early to say. If 20% are truly long term cured, then certainly would be promising, particularly for person &lt;60yo with high risk SMM. If everyone eventually relapses, then it\u2019s not a paradigm shift and best we could hope for is incremental progress.", "source": "Twitter Web App", "created_at": "2022-12-08T20:05:58.000Z", "edit_history_tweet_ids": ["1600944799451738113"], "author_id": "1105483475296178176", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600941543136710657"}], "id": "1600944799451738113", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600938853308645376"}, {"text": "Which is why the very low rates of sustained MRD negativity rates (23% on intent to treat) with an aggressive approach of KRD&gt;transplant&gt; maintenance is so troubling.\n\n#mmsm #ASH22\n\nhttps://t.co/2x1vesjxNo https://t.co/rpUH4UYKFX", "source": "Twitter Web App", "entities": {"annotations": [{"start": 45, "end": 47, "probability": 0.5594, "type": "Other", "normalized_text": "MRD"}, {"start": 122, "end": 124, "probability": 0.4572, "type": "Other", "normalized_text": "KRD"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/2x1vesjxNo", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}, {"start": 212, "end": 235, "url": "https://t.co/rpUH4UYKFX", "expanded_url": "https://twitter.com/chadinabhan/status/1600901994658418688", "display_url": "twitter.com/chadinabhan/st\u2026"}], "hashtags": [{"start": 174, "end": 179, "tag": "mmsm"}, {"start": 180, "end": 186, "tag": "ASH22"}]}, "created_at": "2022-12-08T19:42:21.000Z", "edit_history_tweet_ids": ["1600938853308645376"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600901994658418688"}], "id": "1600938853308645376", "conversation_id": "1600938853308645376"}, {"entities": {"mentions": [{"start": 177, "end": 192, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 65, "end": 67, "probability": 0.7525, "type": "Other", "normalized_text": "MRD"}, {"start": 171, "end": 175, "probability": 0.4795, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 193, "end": 216, "url": "https://t.co/b6P5onvY5g", "expanded_url": "https://twitter.com/vincentrk/status/1600901502654361600", "display_url": "twitter.com/vincentrk/stat\u2026"}], "hashtags": [{"start": 170, "end": 176, "tag": "ASH22"}]}, "text": "I love the fact that this is a fixed duration study and explores MRD. I believe curing a disease requires eradication at the molecular level. Trials will determine that. #ASH22 @ASH_hematology https://t.co/b6P5onvY5g", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:15:53.000Z", "edit_history_tweet_ids": ["1600901994658418688"], "author_id": "2212735524", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600901502654361600"}], "id": "1600901994658418688", "conversation_id": "1600901994658418688"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 20, "username": "VincentRK", "id": "24261916"}, {"start": 21, "end": 31, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 94, "end": 96, "probability": 0.6127, "type": "Other", "normalized_text": "Len"}]}, "text": "@ManniMD1 @VincentRK @myelomaMD if thats the case why do some people consider inc the dose of Len from 10 to 15 mg in the maintiance setting ?", "source": "Twitter Web App", "created_at": "2022-12-08T17:36:45.000Z", "edit_history_tweet_ids": ["1600907245419900928"], "author_id": "964268621655695360", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600848852235403264"}], "id": "1600907245419900928", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "HemSandoval", "id": "4067920889"}, {"start": 13, "end": 23, "username": "VincentRK", "id": "24261916"}, {"start": 24, "end": 34, "username": "myelomaMD", "id": "301568235"}]}, "text": "@HemSandoval @VincentRK @myelomaMD This trial doesnt necessarily answer that question specifically. It is thought provoking though.", "source": "Twitter Web App", "created_at": "2022-12-08T16:27:46.000Z", "edit_history_tweet_ids": ["1600889885212037130"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600879155930755072"}], "id": "1600889885212037130", "in_reply_to_user_id": "4067920889", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 20, "username": "VincentRK", "id": "24261916"}, {"start": 21, "end": 31, "username": "myelomaMD", "id": "301568235"}], "annotations": [{"start": 129, "end": 131, "probability": 0.6958, "type": "Other", "normalized_text": "Len"}]}, "text": "@ManniMD1 @VincentRK @myelomaMD So the strategy of increasing len dose from 10 to 25 mg on a pt that is having biochemical while Len maintenance is probably not useful?. Very good study!", "source": "Twitter for iPhone", "created_at": "2022-12-08T15:45:08.000Z", "edit_history_tweet_ids": ["1600879155930755072"], "author_id": "4067920889", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600848852235403264"}], "id": "1600879155930755072", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600848852235403264"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 71, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 86, "username": "DavidSteensma", "id": "2739065578"}, {"start": 87, "end": 97, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 98, "end": 111, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 112, "end": 122, "username": "VincentRK", "id": "24261916"}, {"start": 123, "end": 133, "username": "myelomaMD", "id": "301568235"}, {"start": 134, "end": 143, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 338, "end": 344, "probability": 0.6744, "type": "Other", "normalized_text": "twitter"}]}, "text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy Theres great advice already given here by people smarter than me.\n\nMost importantly, reassure yourself that something truly practice changing will find your attention through news/conversations/twitter. You wont miss it. I recommend focusing on networking/socializing/having fun\ud83d\ude00", "source": "Twitter Web App", "created_at": "2022-12-08T04:16:51.000Z", "edit_history_tweet_ids": ["1600705945558224896"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "id": "1600705945558224896", "in_reply_to_user_id": "626650397", "conversation_id": "1600642889280798721"}, {"entities": {"mentions": [{"start": 141, "end": 155, "username": "CyclingDoctor", "id": "23036480"}, {"start": 156, "end": 168, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 169, "end": 181, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 182, "end": 197, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 198, "end": 207, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 208, "end": 222, "username": "DavidSteensma", "id": "2739065578"}, {"start": 223, "end": 233, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 234, "end": 247, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 248, "end": 258, "username": "VincentRK", "id": "24261916"}, {"start": 259, "end": 269, "username": "myelomaMD", "id": "301568235"}, {"start": 270, "end": 279, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 63, "end": 69, "probability": 0.6243, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 62, "end": 70, "tag": "ASH2022"}]}, "text": "As a trainee who\u2019s overwhelmed by the volume of abstracts for #ASH2022, any advice on filtering/reviewing/scheduling from the senior folks?\n\n@CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy", "source": "Twitter for iPhone", "created_at": "2022-12-08T00:06:17.000Z", "edit_history_tweet_ids": ["1600642889280798721"], "author_id": "626650397", "lang": "en", "id": "1600642889280798721", "conversation_id": "1600642889280798721"}, {"text": "Who else is frantically trying to finish up their clinic today prior to #ASH22 flight?", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 73, "end": 77, "probability": 0.5744, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 72, "end": 78, "tag": "ASH22"}]}, "created_at": "2022-12-08T02:55:37.000Z", "edit_history_tweet_ids": ["1600685500339171330"], "author_id": "419595308", "lang": "en", "id": "1600685500339171330", "conversation_id": "1600685500339171330"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 33, "username": "sykristinsson", "id": "3078258341"}, {"start": 171, "end": 185, "username": "Intermountain", "id": "17363477"}, {"start": 226, "end": 234, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 73, "end": 76, "probability": 0.9173, "type": "Place", "normalized_text": "Utah"}, {"start": 122, "end": 125, "probability": 0.4842, "type": "Other", "normalized_text": "PCPs"}, {"start": 154, "end": 160, "probability": 0.5518, "type": "Other", "normalized_text": "iSTOPMM"}]}, "text": "@ManniMD1 @iStopMM @sykristinsson Very nice! We are changing practice in Utah for sure :). I gave a short 15 mins talk to PCPs about this and others from iSTOPMM today at @Intermountain. We are surely spreading the great work @iStopMM team has done!", "source": "Twitter Web App", "created_at": "2022-12-07T19:54:22.000Z", "edit_history_tweet_ids": ["1600579488911216640"], "author_id": "3018932371", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600545405540126720"}], "id": "1600579488911216640", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 25, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 26, "end": 34, "username": "iStopMM", "id": "844232399319941122"}, {"start": 35, "end": 49, "username": "sykristinsson", "id": "3078258341"}]}, "text": "@AaronGoodman33 @ManniMD1 @iStopMM @sykristinsson I am also very interested...", "source": "Twitter Web App", "created_at": "2022-12-07T18:29:48.000Z", "edit_history_tweet_ids": ["1600558207487082496"], "author_id": "1163750299", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600546340873781248"}], "id": "1600558207487082496", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 26, "end": 34, "username": "iStopMM", "id": "844232399319941122"}, {"start": 68, "end": 81, "username": "ingigerdursv", "id": "740181058210107392"}], "annotations": [{"start": 85, "end": 91, "probability": 0.6196, "type": "Other", "normalized_text": "thunder"}]}, "text": "@ManniMD1 @AaronGoodman33 @iStopMM Sounds great! Please don't steal @ingigerdursv \u00b4s thunder :)", "source": "Twitter Web App", "created_at": "2022-12-07T17:47:00.000Z", "edit_history_tweet_ids": ["1600547436505743365"], "author_id": "3078258341", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600546555081027584"}], "id": "1600547436505743365", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 33, "username": "sykristinsson", "id": "3078258341"}]}, "text": "@ManniMD1 @iStopMM @sykristinsson can you send me the talk?", "source": "Twitter Web App", "created_at": "2022-12-07T17:42:39.000Z", "edit_history_tweet_ids": ["1600546340873781248"], "author_id": "854692626015993857", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600545405540126720"}], "id": "1600546340873781248", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600545405540126720"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "PallawiTorkaMD", "id": "918471705408016384"}, {"start": 16, "end": 32, "username": "PrashantTembha1", "id": "1160422800709959680"}, {"start": 33, "end": 49, "username": "DrRahulBhargav1", "id": "1125993236105875458"}, {"start": 50, "end": 62, "username": "Prasshmehta", "id": "1131767204972716032"}, {"start": 63, "end": 76, "username": "DrSwami_Iyer", "id": "91581868"}, {"start": 77, "end": 89, "username": "NitinJainMD", "id": "2756778469"}, {"start": 90, "end": 103, "username": "BldCancerDoc", "id": "2809497047"}], "annotations": [{"start": 164, "end": 170, "probability": 0.5236, "type": "Other", "normalized_text": "ASH2023"}], "hashtags": [{"start": 163, "end": 171, "tag": "ASH2023"}]}, "text": "@PallawiTorkaMD @PrashantTembha1 @DrRahulBhargav1 @Prasshmehta @DrSwami_Iyer @NitinJainMD @BldCancerDoc \ud83d\ude2d\ud83d\ude2d Would have loved to connect. Will definitely see you at #ASH2023 \ud83d\ude0d", "source": "Twitter for Android", "created_at": "2022-12-07T13:44:52.000Z", "edit_history_tweet_ids": ["1600486501405450240"], "author_id": "75550503", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600485048020615170"}], "id": "1600486501405450240", "in_reply_to_user_id": "918471705408016384", "conversation_id": "1600485048020615170"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 43, "end": 49, "probability": 0.6717, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@ManniMD1 But how do u treat a 45 year old myeloma in cr 2 in a country where there is no car T cells", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:55:27.000Z", "edit_history_tweet_ids": ["1600323073173258245"], "author_id": "1336329089100046339", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600320621426397184"}], "id": "1600323073173258245", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1600320621426397184"}, {"entities": {"mentions": [{"start": 4, "end": 12, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 62, "end": 66, "probability": 0.7091, "type": "Other", "normalized_text": "ASH22"}, {"start": 223, "end": 233, "probability": 0.986, "type": "Place", "normalized_text": "New Orleans"}], "urls": [{"start": 236, "end": 259, "url": "https://t.co/UdAS2UvU8m", "expanded_url": "https://twitter.com/sykristinsson/status/1600123462827184128/photo/1", "display_url": "pic.twitter.com/UdAS2UvU8m", "media_key": "3_1600122050370277376"}], "hashtags": [{"start": 61, "end": 67, "tag": "ASH22"}]}, "text": "The @iStopMM team is very excited to present our findings at #ASH22\n\nPresentations from the study are, like before, primarily performed by medical student, PhD students, and postdocs. I am so proud of the team!\n\nSee you in New Orleans! https://t.co/UdAS2UvU8m", "source": "Twitter Web App", "created_at": "2022-12-06T13:42:17.000Z", "edit_history_tweet_ids": ["1600123462827184128"], "author_id": "3078258341", "lang": "en", "id": "1600123462827184128", "conversation_id": "1600123462827184128"}, {"entities": {"mentions": [{"start": 83, "end": 91, "username": "mtmdphd", "id": "190337035"}], "annotations": [{"start": 17, "end": 21, "probability": 0.8022, "type": "Other", "normalized_text": "ASH22"}, {"start": 78, "end": 81, "probability": 0.5225, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 92, "end": 115, "url": "https://t.co/nlLQdDOygp", "expanded_url": "https://twitter.com/ManniMD1/status/1599779550753193985", "display_url": "twitter.com/ManniMD1/statu\u2026"}], "hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}, {"start": 77, "end": 82, "tag": "mmsm"}]}, "text": "A great list of #ASH22 abstracts with immediately clinically actionable data #mmsm @mtmdphd https://t.co/nlLQdDOygp", "source": "Twitter for iPhone", "created_at": "2022-12-06T00:19:27.000Z", "edit_history_tweet_ids": ["1599921424277250050"], "author_id": "140966169", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599779550753193985"}], "id": "1599921424277250050", "conversation_id": "1599921424277250050"}, {"text": "Attempting to get my email inbox to zero before #ASH22 - it currently sits at 916.", "source": "Twitter Web App", "entities": {"annotations": [{"start": 49, "end": 53, "probability": 0.5612, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 48, "end": 54, "tag": "ASH22"}]}, "created_at": "2022-12-06T02:08:27.000Z", "edit_history_tweet_ids": ["1599948855797170176"], "author_id": "284694610", "lang": "en", "id": "1599948855797170176", "conversation_id": "1599948855797170176"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 20, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 28, "end": 34, "probability": 0.5706, "type": "Other", "normalized_text": "GRIFFIN"}, {"start": 61, "end": 63, "probability": 0.7951, "type": "Other", "normalized_text": "RCT"}]}, "text": "@ManniMD1 @VincentRK Wasn\u2019t GRIFFIN an open label Phase 2 vs RCT and Phase 3 \n\nDoes that explain it ?", "source": "Twitter for iPhone", "created_at": "2022-12-05T23:54:51.000Z", "edit_history_tweet_ids": ["1599915232733761536"], "author_id": "964268621655695360", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599912628138430465"}], "id": "1599915232733761536", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599838360419213312"}, {"text": "Ahead of #ASH22 here are my updated algorithms for current treatment of myeloma. https://t.co/xj2USXFneM", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 10, "end": 14, "probability": 0.6688, "type": "Other", "normalized_text": "ASH22"}, {"start": 72, "end": 78, "probability": 0.7083, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 81, "end": 104, "url": "https://t.co/xj2USXFneM", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312/photo/1", "display_url": "pic.twitter.com/xj2USXFneM", "media_key": "3_1599838350965411849"}, {"start": 81, "end": 104, "url": "https://t.co/xj2USXFneM", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312/photo/1", "display_url": "pic.twitter.com/xj2USXFneM", "media_key": "3_1599838350977994756"}, {"start": 81, "end": 104, "url": "https://t.co/xj2USXFneM", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312/photo/1", "display_url": "pic.twitter.com/xj2USXFneM", "media_key": "3_1599838350969606151"}, {"start": 81, "end": 104, "url": "https://t.co/xj2USXFneM", "expanded_url": "https://twitter.com/VincentRK/status/1599838360419213312/photo/1", "display_url": "pic.twitter.com/xj2USXFneM", "media_key": "3_1599838350969606149"}], "hashtags": [{"start": 9, "end": 15, "tag": "ASH22"}]}, "created_at": "2022-12-05T18:49:23.000Z", "edit_history_tweet_ids": ["1599838360419213312"], "author_id": "24261916", "lang": "en", "id": "1599838360419213312", "conversation_id": "1599838360419213312"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "EhsanMalekMD", "id": "3344279667"}, {"start": 14, "end": 23, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 24, "end": 39, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 40, "end": 54, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 55, "end": 67, "username": "End_myeloma", "id": "2538011298"}], "annotations": [{"start": 101, "end": 102, "probability": 0.9621, "type": "Place", "normalized_text": "US"}, {"start": 128, "end": 130, "probability": 0.4608, "type": "Other", "normalized_text": "Len"}, {"start": 219, "end": 221, "probability": 0.5729, "type": "Other", "normalized_text": "Len"}]}, "text": "@EhsanMalekMD @ManniMD1 @AaronGoodman33 @SagarLonialMD @End_myeloma We don\u2019t make guidelines for the US only. In most countries Len is $100 per month or less. And once patent problems end in a couple years we will have Len at that price here as well.", "source": "Twitter for iPhone", "created_at": "2022-12-05T19:59:20.000Z", "edit_history_tweet_ids": ["1599855963543986178"], "author_id": "24261916", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599854291530919937"}], "id": "1599855963543986178", "in_reply_to_user_id": "3344279667", "conversation_id": "1598826846082121728"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 16, "username": "Optum", "id": "318007077"}]}, "text": "@ManniMD1 @Optum The DM won\u2019t help.  I did this before with another company. I promise it is just so they look good", "source": "Twitter for iPhone", "created_at": "2022-12-02T23:21:32.000Z", "edit_history_tweet_ids": ["1598819684610347014"], "author_id": "854692626015993857", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598812104190218241"}], "id": "1598819684610347014", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1598810402946961409"}, {"entities": {"mentions": [{"start": 26, "end": 41, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 42, "end": 51, "probability": 0.7395, "type": "Other", "normalized_text": "News Daily"}, {"start": 164, "end": 170, "probability": 0.4696, "type": "Other", "normalized_text": "myeloma"}, {"start": 236, "end": 240, "probability": 0.5625, "type": "Other", "normalized_text": "ASH22"}, {"start": 255, "end": 258, "probability": 0.5415, "type": "Other", "normalized_text": "mmsm"}], "hashtags": [{"start": 235, "end": 241, "tag": "ASH22"}, {"start": 254, "end": 259, "tag": "mmsm"}]}, "text": "I am excited to be on the @ASH_hematology News Daily editorial board, and will be covering/attending the meeting this year.\n\nIn this \ud83e\uddf5, I will highlight the top 10 myeloma abstracts that most influence my thought and practice from the #ASH22 meeting!  \n\n#mmsm", "source": "Twitter Web App", "created_at": "2022-11-09T20:23:54.000Z", "edit_history_tweet_ids": ["1590440063263182851"], "author_id": "1269642863924609025", "lang": "en", "id": "1590440063263182851", "conversation_id": "1590440063263182851"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@RnInfection @AaronGoodman33 Ultimately, it is a complex nuanced decision, but there is enough ambiguity here that observing without treatment is a fully appropriate decision that I support when my patients make it. 3/end", "source": "Twitter Web App", "created_at": "2022-12-04T22:42:45.000Z", "edit_history_tweet_ids": ["1599534700225495040"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599534249593696256"}], "id": "1599534700225495040", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "text": "@RnInfection @AaronGoodman33 Data from the German group highlighted in a recent thread I shared indicates that renal failure and compression fractures in absence of preceding lytic lesions are rare. Providing this information provides reassurance to my patients and I try to mention. 2/", "source": "Twitter Web App", "created_at": "2022-12-04T22:40:57.000Z", "edit_history_tweet_ids": ["1599534249593696256"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599533907145535488"}], "id": "1599534249593696256", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "RnInfection", "id": "327808606"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 68, "end": 74, "probability": 0.934, "type": "Other", "normalized_text": "twitter"}, {"start": 174, "end": 176, "probability": 0.6653, "type": "Other", "normalized_text": "SMM"}]}, "text": "@RnInfection @AaronGoodman33 It is tough to answer this w nuance on twitter. In general, depends on patient values/preferences. Every single time, when I\u2019ve seen a high risk SMM and discussed data on len, they\u2019ve elected to observe. \n\nThere is a 2/20/20+cytogenetics model, but also with same limitations. 1/", "source": "Twitter Web App", "created_at": "2022-12-04T22:39:36.000Z", "edit_history_tweet_ids": ["1599533907145535488"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599498447387734016"}], "id": "1599533907145535488", "in_reply_to_user_id": "327808606", "conversation_id": "1599498447387734016"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 38, "end": 43, "probability": 0.5265, "type": "Other", "normalized_text": "Lonial"}, {"start": 82, "end": 86, "probability": 0.6173, "type": "Other", "normalized_text": "HRSMM"}], "urls": [{"start": 277, "end": 300, "url": "https://t.co/DI9GkSqmnV", "expanded_url": "https://twitter.com/SagarLonialMD/status/1599486081061134337", "display_url": "twitter.com/SagarLonialMD/\u2026"}]}, "text": "@ManniMD1 @AaronGoodman33 I asked Dr. Lonial if they do early intervention on all HRSMM pts or are there parameters to further define HR? No two patients are alike and I struggle with the 2-20-20 definition, especially in the absence of any sign of CRAB and standard genetics. https://t.co/DI9GkSqmnV", "source": "Twitter Web App", "created_at": "2022-12-04T20:18:41.000Z", "edit_history_tweet_ids": ["1599498447387734016"], "author_id": "327808606", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1599486081061134337"}], "id": "1599498447387734016", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599498447387734016"}, {"text": "How do patients with smoldering myeloma progress? Is it fracture appearing suddenly without corresponding lesions first seen on serial imaging?\nIs it sudden renal failure?\n\nAn excellent study from Germany in which patients were prospectively observed provides insight\n\nA \ud83e\uddf5\n\n#mmsm", "source": "Twitter Web App", "entities": {"annotations": [{"start": 32, "end": 38, "probability": 0.5863, "type": "Other", "normalized_text": "myeloma"}, {"start": 197, "end": 203, "probability": 0.9543, "type": "Place", "normalized_text": "Germany"}], "hashtags": [{"start": 274, "end": 279, "tag": "mmsm"}]}, "created_at": "2022-11-20T01:28:57.000Z", "edit_history_tweet_ids": ["1594140708679868416"], "author_id": "1269642863924609025", "lang": "en", "id": "1594140708679868416", "conversation_id": "1594140708679868416"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 287, "end": 301, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 54, "end": 57, "probability": 0.6005, "type": "Other", "normalized_text": "CRAB"}, {"start": 108, "end": 109, "probability": 0.4907, "type": "Other", "normalized_text": "KD"}, {"start": 261, "end": 263, "probability": 0.7518, "type": "Other", "normalized_text": "BMB"}]}, "text": "@ManniMD1 @AaronGoodman33 Surely close monitoring for CRAB will reveal progression well before irreversible KD or fractures, even if one pushes into the 2-20-20 high risk? I assume renal failure/fractures don't happen overnight? Looking forward to my appt post BMB with my MM specialist @DrOlaLandgren", "source": "Twitter for iPad", "created_at": "2022-12-03T13:45:48.000Z", "edit_history_tweet_ids": ["1599037186766036993"], "author_id": "327808606", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598828488697708544"}], "id": "1599037186766036993", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1598826846082121728"}, {"text": "5. There is only one poster that I present myself (on the role of anti-CD38 therapy in 11;14 myeloma), meet me at that Session in Hall D on Saturday 5:30 pm . Manuscript already accepted at Blood Cancer Journal, I will share a thread soon!\n\nhttps://t.co/AVYiHqpdgd", "source": "Twitter Web App", "entities": {"annotations": [{"start": 93, "end": 99, "probability": 0.472, "type": "Other", "normalized_text": "myeloma"}, {"start": 190, "end": 209, "probability": 0.9535, "type": "Other", "normalized_text": "Blood Cancer Journal"}], "urls": [{"start": 241, "end": 264, "url": "https://t.co/AVYiHqpdgd", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165541.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy", "description": "Program: Oral and Poster Abstracts Session: 905. Outcomes Research\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Research, health outcomes research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Ghulam Rehman Mohyuddin, MD 1, Rajshekhar Chakraborty, MD 2, Gregory Calip, PhD 3 *, Mustafa S Ascha, PhD, MS 4 *, Xiaoliang Wang, PhD, MPH 5 *, Samuel Rubinstein, MD 6 *, Sascha A. Tuchman, MD, MHS 7, Luciano J. Megala Costa, MD, PhD 8, Benjamin Haaland 9 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165541.html"}]}, "created_at": "2022-12-04T17:40:28.000Z", "edit_history_tweet_ids": ["1599458629513773056"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458628410675200"}], "id": "1599458629513773056", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 19, "end": 30, "username": "AlecBritt4", "id": "1230155192374644736"}], "annotations": [{"start": 73, "end": 79, "probability": 0.6586, "type": "Other", "normalized_text": "myeloma"}, {"start": 135, "end": 137, "probability": 0.7135, "type": "Other", "normalized_text": "MRD"}]}, "text": "4. I did work with @AlecBritt4 on the landscape of maintenance trials in myeloma, including endpoints utilized, control arms, risk and MRD stratification. Whereas this was not accepted for poster presentation, stay tuned for the manuscript.", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:28.000Z", "edit_history_tweet_ids": ["1599458628410675200"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458627282415616"}], "id": "1599458628410675200", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 4, "end": 16, "username": "NamSharmaMD", "id": "1131320725682434049"}], "annotations": [{"start": 73, "end": 80, "probability": 0.2693, "type": "Other", "normalized_text": "Oncology"}, {"start": 86, "end": 92, "probability": 0.3954, "type": "Other", "normalized_text": "Onclive"}, {"start": 151, "end": 155, "probability": 0.635, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 197, "end": 220, "url": "https://t.co/TUXXrgf4Xy", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}], "hashtags": [{"start": 150, "end": 156, "tag": "ASH22"}]}, "text": "3. \n@NamSharmaMD highlights the quality of content presented at Targeted Oncology and Onclive. I am meeting representatives of these organizations at #ASH22 to discuss ways to improve reporting! \n\nhttps://t.co/TUXXrgf4Xy", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458627282415616"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458626057691137"}], "id": "1599458627282415616", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 5, "end": 18, "username": "StijnHentzen", "id": "485202660"}], "urls": [{"start": 254, "end": 277, "url": "https://t.co/Ic00FzASsX", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159807.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Attrition and Withdrawal Amongst Patients with Multiple Myeloma Participating in Randomized Clinical Trials: A Systematic Review", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster II Hematology D isease Topics & Pathways: clinical trials, Research, Clinical Research, Plasma Cell Disorders, Diseases, Adverse Events, Lymphoid Malignancies Stijn Hentzen, MD 1 *, Tomer Meirson 2 *, Kelly Koehn, MD 3, Aaron M Goodman 4, Rajshekhar Chakraborty, MBBS 5, Vinay Prasad 6 *, Douglas W. Sborov, MD 7 and Ghulam Rehman Mohyuddin, MD 8 1 Department of Internal Medicine, Kansas University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159807.html"}]}, "text": "2. \n\n@StijnHentzen presents the first ever detailed analysis of a cohort of oncology trials to ascertain why and how patients drop out of trials. Disease progression, death, toxicity or other reasons such as physician preference?\n\nManuscript in review.\n\nhttps://t.co/Ic00FzASsX", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458626057691137"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458624895877121"}], "id": "1599458626057691137", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 5, "end": 14, "username": "t_etekal", "id": "1002175603"}], "annotations": [{"start": 58, "end": 60, "probability": 0.5382, "type": "Other", "normalized_text": "PFS"}, {"start": 66, "end": 67, "probability": 0.4359, "type": "Other", "normalized_text": "OS"}, {"start": 72, "end": 78, "probability": 0.6338, "type": "Other", "normalized_text": "myeloma"}, {"start": 89, "end": 91, "probability": 0.577, "type": "Other", "normalized_text": "PFS"}, {"start": 116, "end": 122, "probability": 0.5194, "type": "Other", "normalized_text": "myeloma"}, {"start": 153, "end": 155, "probability": 0.6141, "type": "Other", "normalized_text": "BJH"}], "urls": [{"start": 215, "end": 238, "url": "https://t.co/HMsT1voKGs", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163855.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis", "description": "Program: Oral and Poster Abstracts Session: 902. Health Services and Quality\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Plasma Cell Disorders, patient-reported outcomes, Diseases, Lymphoid Malignancies Tommy Etekal 1 *, Kelly Koehn, MD 2, Douglas W. Sborov, MD 3, Brian McClune, DO 4 *, Vinay Prasad 5 *, Alyson Haslam 5 *, Katherine Berger 6 *, Christopher Booth, MD 7 *, Samer", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163855.html"}]}, "text": "1. \n\n@t_etekal presents our work on the surrogacy between PFS and OS in myeloma, and how PFS events are reported in myeloma trials. Paper will be out in BJH soon- will write a full thread to explain our findings. \n\nhttps://t.co/HMsT1voKGs", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:27.000Z", "edit_history_tweet_ids": ["1599458624895877121"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599458623469387777"}], "id": "1599458624895877121", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 135, "end": 150, "username": "huntsmancancer", "id": "20004102"}], "annotations": [{"start": 23, "end": 27, "probability": 0.5885, "type": "Other", "normalized_text": "ASH22"}, {"start": 121, "end": 123, "probability": 0.4909, "type": "Organization", "normalized_text": "ASH"}], "hashtags": [{"start": 22, "end": 28, "tag": "ASH22"}, {"start": 128, "end": 133, "tag": "mmsm"}]}, "text": "So looking forward to #ASH22. I have had the pleasure of mentoring many trainees remotely, who are presenting posters at ASH. \n\n#mmsm \n@huntsmancancer \n\nHere is a thread of some of the work they present.\n\nAlso, if you are a trainee- my DM's are open- would love to meet you!", "source": "Twitter Web App", "created_at": "2022-12-04T17:40:26.000Z", "edit_history_tweet_ids": ["1599458623469387777"], "author_id": "1269642863924609025", "lang": "en", "id": "1599458623469387777", "conversation_id": "1599458623469387777"}, {"entities": {"mentions": [{"start": 96, "end": 108, "username": "TargetedOnc", "id": "726304448"}], "annotations": [{"start": 186, "end": 195, "probability": 0.7822, "type": "Other", "normalized_text": "Karyopharm"}], "urls": [{"start": 217, "end": 240, "url": "https://t.co/lY1whIeggs", "expanded_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma", "display_url": "targetedonc.com/view/clinical-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=orig", "width": 480, "height": 270}, {"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma", "description": "At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.", "unwound_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma"}]}, "text": "Is it fair for us to politely ask (without disrespecting the people being interviewed) who pays @TargetedOnc for this content?\n\nIs it fair to ask them to report money they received from Karyopharm (if any) for this?\n\nhttps://t.co/lY1whIeggs", "source": "Twitter Web App", "created_at": "2022-12-04T16:46:42.000Z", "edit_history_tweet_ids": ["1599445097224892418"], "author_id": "1269642863924609025", "lang": "en", "id": "1599445097224892418", "conversation_id": "1599445097224892418"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "CoachBon", "id": "913851074"}, {"start": 10, "end": 19, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@CoachBon @ManniMD1 This is connected to what I was trying to say yesterday. I absolutely don't want a return to paternalism in medicine, &amp; patients should be involved in making tx decisions  but is it honestly in any pt's best interest to enroll on this study? \ud83e\udd14", "source": "Twitter Web App", "created_at": "2022-12-04T16:27:38.000Z", "edit_history_tweet_ids": ["1599440298840444928"], "author_id": "1302975798304014336", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599416272323690496"}], "id": "1599440298840444928", "in_reply_to_user_id": "913851074", "conversation_id": "1599057168103538690"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "AdiG1993", "id": "1343430777321582593"}, {"start": 10, "end": 22, "username": "nihardesai7", "id": "75550503"}, {"start": 23, "end": 38, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 62, "end": 71, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@AdiG1993 @nihardesai7 @AaronGoodman33 Don't forget the great @ManniMD1!", "source": "Twitter for Android", "created_at": "2022-12-03T21:44:39.000Z", "edit_history_tweet_ids": ["1599157691615584257"], "author_id": "1396562477954093057", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599072194914848773"}], "id": "1599157691615584257", "in_reply_to_user_id": "1343430777321582593", "conversation_id": "1599072194914848773"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 38, "end": 47, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@ManniMD1 I am interested to know how @ManniMD1  you can do an informed consent to enrol in such study?", "source": "Twitter for iPhone", "created_at": "2022-12-03T15:39:25.000Z", "edit_history_tweet_ids": ["1599065779403563008"], "author_id": "774267564", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599057168103538690"}], "id": "1599065779403563008", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599057168103538690"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@ManniMD1 Let me correct you.\n\n\"Should they be offered the opportunity of consenting to participate in a trial\".\n\nEnrollment is not a passive action. People are not treated without knowing the risks/possible benefits.", "source": "Twitter for Android", "created_at": "2022-12-03T15:26:57.000Z", "edit_history_tweet_ids": ["1599062642412306434"], "author_id": "1294745239656202240", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1599057168103538690"}], "id": "1599062642412306434", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1599057168103538690"}, {"text": "Another day, another single arm study in smoldering myeloma. Now with Selinexor with extension to intermediate risk SMM\nWhy do we need this? #mmsm \n\u2705How can this be helpful to pts?\n\u2705How can this be helpful to field?\nWill it be possible to stop doing such studies please?! https://t.co/fl1ickDOLu", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 52, "end": 58, "probability": 0.711, "type": "Other", "normalized_text": "myeloma"}, {"start": 70, "end": 78, "probability": 0.771, "type": "Other", "normalized_text": "Selinexor"}, {"start": 116, "end": 118, "probability": 0.6489, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 272, "end": 295, "url": "https://t.co/fl1ickDOLu", "expanded_url": "https://twitter.com/HadidiSamer/status/1599042085541142528/photo/1", "display_url": "pic.twitter.com/fl1ickDOLu", "media_key": "3_1599042078910169088"}, {"start": 272, "end": 295, "url": "https://t.co/fl1ickDOLu", "expanded_url": "https://twitter.com/HadidiSamer/status/1599042085541142528/photo/1", "display_url": "pic.twitter.com/fl1ickDOLu", "media_key": "3_1599042078901682178"}, {"start": 272, "end": 295, "url": "https://t.co/fl1ickDOLu", "expanded_url": "https://twitter.com/HadidiSamer/status/1599042085541142528/photo/1", "display_url": "pic.twitter.com/fl1ickDOLu", "media_key": "3_1599042078918541315"}], "hashtags": [{"start": 141, "end": 146, "tag": "mmsm"}]}, "created_at": "2022-12-03T14:05:16.000Z", "edit_history_tweet_ids": ["1599042085541142528"], "author_id": "774267564", "lang": "en", "id": "1599042085541142528", "conversation_id": "1599042085541142528"}, {"entities": {"mentions": [{"start": 82, "end": 93, "username": "JackWestMD", "id": "28943421"}, {"start": 95, "end": 110, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 112, "end": 121, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 200, "end": 209, "probability": 0.8552, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 212, "end": 219, "probability": 0.5147, "type": "Other", "normalized_text": "Oncology"}], "hashtags": [{"start": 199, "end": 210, "tag": "MedTwitter"}, {"start": 211, "end": 220, "tag": "Oncology"}]}, "text": "Anyone have any additional recommendations to follow for solid tumors (similar to @JackWestMD, @AaronGoodman33, @ManniMD1)?  People who are a little more critical and not afraid to be controversial. #MedTwitter #Oncology.", "source": "Twitter for iPhone", "created_at": "2022-12-02T16:11:26.000Z", "edit_history_tweet_ids": ["1598711446094987267"], "author_id": "1106254878387642368", "lang": "en", "id": "1598711446094987267", "conversation_id": "1598711446094987267"}, {"text": "Note FLCr&gt;100 even with proteinuria had median time to myeloma of over 3 years. How is this a myeloma defining event where expected should be 80%@2 years", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 5, "end": 8, "probability": 0.7016, "type": "Other", "normalized_text": "FLCr"}, {"start": 27, "end": 37, "probability": 0.5552, "type": "Other", "normalized_text": "proteinuria"}]}, "created_at": "2022-08-27T00:35:27.000Z", "edit_history_tweet_ids": ["1563324275536236544"], "author_id": "1316325128", "lang": "en", "id": "1563324275536236544", "conversation_id": "1563324275536236544"}, {"text": "I have been told it cruel to observe smoldering myeloma as patients will develop broken hips and backs.  I don't want this to happen!  \n\nShow me data treating prevents this (as opposed to PET+ bone lesion or Hb 10) and I will be glad to start treating smoldering myeloma.", "source": "Twitter Web App", "entities": {"annotations": [{"start": 48, "end": 54, "probability": 0.7259, "type": "Other", "normalized_text": "myeloma"}, {"start": 263, "end": 269, "probability": 0.6445, "type": "Other", "normalized_text": "myeloma"}]}, "created_at": "2022-12-02T23:49:59.000Z", "edit_history_tweet_ids": ["1598826846082121728"], "author_id": "854692626015993857", "lang": "en", "id": "1598826846082121728", "conversation_id": "1598826846082121728"}, {"entities": {"mentions": [{"start": 88, "end": 103, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 104, "end": 113, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 114, "end": 130, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 131, "end": 142, "username": "dgermain21", "id": "18821994"}, {"start": 143, "end": 157, "username": "MichaelJSlade", "id": "626650397"}, {"start": 158, "end": 169, "username": "RPachynski", "id": "1179604816198275072"}], "annotations": [{"start": 45, "end": 55, "probability": 0.6667, "type": "Other", "normalized_text": "ASCO Survey"}], "urls": [{"start": 172, "end": 195, "url": "https://t.co/XqwyQ1upQh", "expanded_url": "https://old-prod.asco.org/sites/new-www.asco.org/files/ASCO-Prior-Auth-Survey-Summary-November-2022.pdf", "display_url": "old-prod.asco.org/sites/new-www.\u2026", "status": 200, "unwound_url": "https://old-prod.asco.org/sites/new-www.asco.org/files/ASCO-Prior-Auth-Survey-Summary-November-2022.pdf"}, {"start": 196, "end": 219, "url": "https://t.co/xgnUILon9N", "expanded_url": "https://twitter.com/CyclingDoctor/status/1598821507920076800/photo/1", "display_url": "pic.twitter.com/xgnUILon9N", "media_key": "3_1598821403175915521"}, {"start": 196, "end": 219, "url": "https://t.co/xgnUILon9N", "expanded_url": "https://twitter.com/CyclingDoctor/status/1598821507920076800/photo/1", "display_url": "pic.twitter.com/xgnUILon9N", "media_key": "3_1598821457081106432"}]}, "text": "Sobering (but not surprising) results of the ASCO Survey regarding prior authorization.\n@AaronGoodman33 @ManniMD1 @RahulBanerjeeMD @dgermain21 @MichaelJSlade @RPachynski \n\nhttps://t.co/XqwyQ1upQh https://t.co/xgnUILon9N", "source": "Twitter Web App", "created_at": "2022-12-02T23:28:46.000Z", "edit_history_tweet_ids": ["1598821507920076800"], "author_id": "23036480", "lang": "en", "id": "1598821507920076800", "conversation_id": "1598821507920076800"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 61, "end": 65, "probability": 0.6323, "type": "Other", "normalized_text": "Manni"}]}, "text": "@ManniMD1 We regret the inconvenience this issue has caused, Manni. If you'd like to speak to someone regarding your concerns, please private message us your name and phone number. Thank you", "source": "Sprinklr", "created_at": "2022-12-02T22:49:01.000Z", "edit_history_tweet_ids": ["1598811501393068033"], "author_id": "318007077", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598810402946961409"}], "id": "1598811501393068033", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1598810402946961409"}, {"entities": {"mentions": [{"start": 54, "end": 68, "username": "BloodAdvances", "id": "732570175162179585"}], "annotations": [{"start": 116, "end": 135, "probability": 0.5583, "type": "Other", "normalized_text": "clonal hematopoiesis"}, {"start": 213, "end": 217, "probability": 0.3478, "type": "Other", "normalized_text": "AMLsm"}], "urls": [{"start": 221, "end": 244, "url": "https://t.co/lezDJSksTa", "expanded_url": "https://doi.org/10.1182/bloodadvances.2022008521", "display_url": "doi.org/10.1182/blooda\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1598345132264169472/ybIPLxso?format=png&name=orig", "width": 120, "height": 154}, {"url": "https://pbs.twimg.com/news_img/1598345132264169472/ybIPLxso?format=png&name=150x150", "width": 120, "height": 120}], "status": 200, "title": "Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones", "description": "Key Points. Clonal hematopoiesis (CH) can be confined to specific bone marrow spaces and may be eliminated through surgical extraction.Patients with osteoarthri", "unwound_url": "https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022008521/493378/Paired-bone-marrow-and-peripheral-blood-samples"}], "hashtags": [{"start": 205, "end": 211, "tag": "mdssm"}, {"start": 212, "end": 218, "tag": "AMLsm"}]}, "text": "Hips don't lie: my fellowship project found a home at @BloodAdvances. I'm excited about the questions we raised: Is clonal hematopoiesis spatially confined to specific marrow spaces? Can surgery cure it?  #mdssm #AMLsm \n\nhttps://t.co/lezDJSksTa", "source": "Twitter Web App", "created_at": "2022-12-01T15:55:48.000Z", "edit_history_tweet_ids": ["1598345125419044864"], "author_id": "1024366977425526784", "lang": "en", "id": "1598345125419044864", "conversation_id": "1598345125419044864"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 34, "end": 36, "probability": 0.4907, "type": "Organization", "normalized_text": "ITT"}, {"start": 75, "end": 77, "probability": 0.689, "type": "Other", "normalized_text": "MRD"}, {"start": 117, "end": 121, "probability": 0.9698, "type": "Other", "normalized_text": "COVID"}]}, "text": "@ManniMD1 Please note that 23% is ITT and is underestimated due to lack of MRD testing during the first two waves of COVID.", "source": "Twitter for Android", "created_at": "2022-12-01T05:06:43.000Z", "edit_history_tweet_ids": ["1598181778006585345"], "author_id": "1335161063382376448", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598181396430090240"}], "id": "1598181778006585345", "in_reply_to_user_id": "1335161063382376448", "conversation_id": "1598124890405883904"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 22, "username": "TMSchmidtMD", "id": "1022478983760359424"}, {"start": 23, "end": 39, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 40, "end": 53, "username": "MeeraMohanMD", "id": "1087342265645875200"}, {"start": 54, "end": 66, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 71, "end": 75, "probability": 0.6217, "type": "Other", "normalized_text": "Manni"}]}, "text": "@ManniMD1 @TMSchmidtMD @RahulBanerjeeMD @MeeraMohanMD @HadidiSamer Dr. Manni anyway to get a copy of this paper??", "source": "Twitter Web App", "created_at": "2022-12-01T02:16:35.000Z", "edit_history_tweet_ids": ["1598138965009502208"], "author_id": "913851074", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1403346335768666113"}], "id": "1598138965009502208", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1403346298284163075"}, {"entities": {"mentions": [{"start": 42, "end": 57, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 59, "end": 72, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 81, "end": 91, "probability": 0.4243, "type": "Other", "normalized_text": "Ouchveridze"}, {"start": 126, "end": 127, "probability": 0.8482, "type": "Organization", "normalized_text": "KU"}], "urls": [{"start": 131, "end": 154, "url": "https://t.co/3VQ0zztMUu", "expanded_url": "https://bit.ly/3vekyaH", "display_url": "bit.ly/3vekyaH"}, {"start": 264, "end": 287, "url": "https://t.co/6OT4lcqRnr", "expanded_url": "https://twitter.com/ManniMD1/status/1403346298284163075/photo/1", "display_url": "pic.twitter.com/6OT4lcqRnr", "media_key": "3_1403339569718829058"}, {"start": 264, "end": 287, "url": "https://t.co/6OT4lcqRnr", "expanded_url": "https://twitter.com/ManniMD1/status/1403346298284163075/photo/1", "display_url": "pic.twitter.com/6OT4lcqRnr", "media_key": "3_1403339569903374348"}], "hashtags": [{"start": 258, "end": 263, "tag": "mmsm"}]}, "text": "Check out newest paper from dream team of @AaronGoodman33, @VPrasadMDMPH, and Dr Ouchveridze (amazing first year HO fellow at KU)\n\nhttps://t.co/3VQ0zztMUu.\n\nIn this paper, we explore the landscape of smoldering myeloma trials- the past, present and future.\n\n#mmsm https://t.co/6OT4lcqRnr", "source": "Twitter Web App", "created_at": "2021-06-11T13:40:05.000Z", "edit_history_tweet_ids": ["1403346298284163075"], "author_id": "1269642863924609025", "lang": "en", "id": "1403346298284163075", "conversation_id": "1403346298284163075"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "text": "@ManniMD1 Maybe one such study with very very careful consent.  After that we need know more.", "source": "Twitter for iPhone", "created_at": "2022-12-01T02:02:54.000Z", "edit_history_tweet_ids": ["1598135519157723137"], "author_id": "854692626015993857", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598135332691595264"}], "id": "1598135519157723137", "in_reply_to_user_id": "1269642863924609025", "conversation_id": "1598134143954857984"}, {"text": "Asymptomatic patients are dying on single arm treatment studies of smoldering myeloma. We need to stop doing this. https://t.co/bVkD30HCBL", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 78, "end": 84, "probability": 0.7282, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 115, "end": 138, "url": "https://t.co/bVkD30HCBL", "expanded_url": "https://twitter.com/ManniMD1/status/1598124890405883904", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "created_at": "2022-12-01T01:57:26.000Z", "edit_history_tweet_ids": ["1598134143954857984"], "author_id": "854692626015993857", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1598124890405883904"}], "id": "1598134143954857984", "conversation_id": "1598134143954857984"}, {"text": "Amongst most profound observations from #ASH22 \n\nIf sustained MRD neg is best surrogate for cure, note that aggressive attempt to \"cure\" smoldering MM using KRD&gt;trans&gt;maintenance led to only 23% sustained MRD neg.\n\nImmense implications for smoldering MM/early intervention.\n\n#mmsm https://t.co/EK29OHpfAG", "source": "Twitter Web App", "entities": {"annotations": [{"start": 41, "end": 45, "probability": 0.6528, "type": "Other", "normalized_text": "ASH22"}, {"start": 62, "end": 64, "probability": 0.6256, "type": "Other", "normalized_text": "MRD"}, {"start": 157, "end": 159, "probability": 0.4539, "type": "Other", "normalized_text": "KRD"}, {"start": 211, "end": 213, "probability": 0.4711, "type": "Other", "normalized_text": "MRD"}, {"start": 282, "end": 285, "probability": 0.505, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 287, "end": 310, "url": "https://t.co/EK29OHpfAG", "expanded_url": "https://twitter.com/ManniMD1/status/1598124890405883904/photo/1", "display_url": "pic.twitter.com/EK29OHpfAG", "media_key": "3_1598124526486769666"}], "hashtags": [{"start": 40, "end": 46, "tag": "ASH22"}, {"start": 281, "end": 286, "tag": "mmsm"}]}, "created_at": "2022-12-01T01:20:40.000Z", "edit_history_tweet_ids": ["1598124890405883904"], "author_id": "1269642863924609025", "lang": "en", "id": "1598124890405883904", "conversation_id": "1598124890405883904"}, {"entities": {"mentions": [{"start": 46, "end": 55, "username": "ManniMD1", "id": "1269642863924609025"}], "urls": [{"start": 56, "end": 79, "url": "https://t.co/Iz83B0fxYC", "expanded_url": "https://twitter.com/ManniMD1/status/1595575470824648705", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "Analyze paper while you read it! \n\nGreat \ud83e\uddf5 by @ManniMD1 https://t.co/Iz83B0fxYC", "source": "Twitter Web App", "created_at": "2022-11-25T13:25:19.000Z", "edit_history_tweet_ids": ["1596132927179722753"], "author_id": "939599146608152576", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1595575470824648705"}], "id": "1596132927179722753", "conversation_id": "1596132927179722753"}, {"entities": {"mentions": [{"start": 28, "end": 37, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 39, "end": 42, "probability": 0.5266, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 44, "end": 67, "url": "https://t.co/6LjzfI3q9N", "expanded_url": "https://twitter.com/ManniMD1/status/1595575470824648705", "display_url": "twitter.com/ManniMD1/statu\u2026"}], "hashtags": [{"start": 38, "end": 43, "tag": "mmsm"}]}, "text": "Great critical appraisal by @ManniMD1\n#mmsm https://t.co/6LjzfI3q9N", "source": "Twitter for iPhone", "created_at": "2022-11-28T15:21:10.000Z", "edit_history_tweet_ids": ["1597249248021852160"], "author_id": "951231260306718720", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1595575470824648705"}], "id": "1597249248021852160", "conversation_id": "1597249248021852160"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 14, "end": 23, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 24, "end": 30, "probability": 0.6139, "type": "Other", "normalized_text": "OncLive"}]}, "text": "@VPrasadMDMPH @ManniMD1 OncLive is the advertising branch of pharma disguised as academic thought leaders discussing data.  I have no problem if it exists but we should call it exactly what it is.", "source": "Twitter for iPhone", "created_at": "2022-11-27T22:25:18.000Z", "edit_history_tweet_ids": ["1596993595986542592"], "author_id": "854692626015993857", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596988450385063937"}], "id": "1596993595986542592", "in_reply_to_user_id": "1194962714", "conversation_id": "1596988450385063937"}, {"entities": {"mentions": [{"start": 70, "end": 79, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 80, "end": 95, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 23, "end": 29, "probability": 0.7028, "type": "Other", "normalized_text": "OncLive"}, {"start": 34, "end": 36, "probability": 0.5578, "type": "Organization", "normalized_text": "ASH"}, {"start": 212, "end": 214, "probability": 0.7358, "type": "Organization", "normalized_text": "FDA"}, {"start": 245, "end": 246, "probability": 0.8433, "type": "Place", "normalized_text": "US"}], "urls": [{"start": 97, "end": 120, "url": "https://t.co/Ts55UVUijG", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}, {"start": 269, "end": 292, "url": "https://t.co/UkDabmrsYe", "expanded_url": "https://twitter.com/OncLive/status/1596987367466094593", "display_url": "twitter.com/OncLive/status\u2026"}]}, "text": "This is why we studied OncLive at ASH &amp; found it loaded with bias\n@ManniMD1 @AaronGoodman33 \nhttps://t.co/Ts55UVUijG\n\nLook at this tweet\nYou wouldn't guess from it, but this drug FAILED TO IMPROVE OS and the FDA is about to YANK it from the US MARKET\n\nDo better \ud83d\udc47\ud83d\udc47 https://t.co/UkDabmrsYe", "source": "Twitter Web App", "created_at": "2022-11-27T22:04:51.000Z", "edit_history_tweet_ids": ["1596988450385063937"], "author_id": "1194962714", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596987367466094593"}], "id": "1596988450385063937", "conversation_id": "1596988450385063937"}, {"entities": {"mentions": [{"start": 77, "end": 92, "username": "justin_denholm", "id": "2601159530"}, {"start": 110, "end": 118, "username": "syctong", "id": "218845908"}, {"start": 161, "end": 177, "username": "JAMAInternalMed", "id": "54664757"}], "annotations": [{"start": 94, "end": 102, "probability": 0.557, "type": "Other", "normalized_text": "Dr Street"}, {"start": 122, "end": 127, "probability": 0.4868, "type": "Other", "normalized_text": "VIDSJC"}, {"start": 241, "end": 257, "probability": 0.403, "type": "Other", "normalized_text": "aureus bacteremia"}], "urls": [{"start": 259, "end": 282, "url": "https://t.co/EP4B6UPuxj", "expanded_url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2652832", "display_url": "jamanetwork.com/journals/jamai\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1596684112395370497/rYgBIt4q?format=png&name=orig", "width": 950, "height": 631}, {"url": "https://pbs.twimg.com/news_img/1596684112395370497/rYgBIt4q?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Association of Evidence-Based Care Processes and Mortality in Staphylococcus aureus Bacteremia", "description": "This cohort study examines the association of evidence-based care processes in routine care for Staphylococcus aureus bacteremia with mortality at Veterans Health Administration hospitals.", "unwound_url": "https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2652832"}, {"start": 283, "end": 306, "url": "https://t.co/IQ2DwR1Qee", "expanded_url": "https://twitter.com/Eddie_Cliff/status/1596684108184408066/photo/1", "display_url": "pic.twitter.com/IQ2DwR1Qee", "media_key": "3_1596678951505694720"}], "hashtags": [{"start": 121, "end": 128, "tag": "VIDSJC"}]}, "text": "Immortal time bias: a \ud83e\uddf5\nWhen I was an infectious diseases intern, I attended @justin_denholm, Dr Street &amp; @syctong's #VIDSJC journal club, we discussed this @JAMAInternalMed paper: Association of Evidence-Based Care w Mortality in staph aureus bacteremia https://t.co/EP4B6UPuxj https://t.co/IQ2DwR1Qee", "source": "Twitter Web App", "created_at": "2022-11-27T01:55:31.000Z", "edit_history_tweet_ids": ["1596684108184408066"], "author_id": "74081884", "lang": "en", "id": "1596684108184408066", "conversation_id": "1596684108184408066"}, {"entities": {"mentions": [{"start": 64, "end": 78, "username": "DrRakeshPopat", "id": "1202400046760841218"}, {"start": 87, "end": 101, "username": "DrSanjayPopat", "id": "780503912260468736"}], "annotations": [{"start": 28, "end": 47, "probability": 0.4838, "type": "Other", "normalized_text": "HealthcareUnfiltered"}, {"start": 117, "end": 133, "probability": 0.7427, "type": "Other", "normalized_text": "cuss \u201cSurrogate E"}], "urls": [{"start": 284, "end": 307, "url": "https://t.co/O35hPkOM99", "expanded_url": "https://twitter.com/chadinabhan/status/1596864022548185089/video/1", "display_url": "pic.twitter.com/O35hPkOM99", "media_key": "7_1596863968529768449"}], "hashtags": [{"start": 27, "end": 48, "tag": "HealthcareUnfiltered"}]}, "text": "This week; this Tuesday on #HealthcareUnfiltered, two brothers \u2066@DrRakeshPopat\u2069 &amp; \u2066@DrSanjayPopat\u2069 join me to discuss \u201cSurrogate Endpoints\u201d in solid &amp; liquid tumors.\n\nAmazing discussion: pros &amp; cons. Surrogates are here to stay, so what can we do best &amp; next. A clip. https://t.co/O35hPkOM99", "source": "Twitter for iPhone", "created_at": "2022-11-27T13:50:25.000Z", "edit_history_tweet_ids": ["1596864022548185089"], "author_id": "2212735524", "lang": "en", "id": "1596864022548185089", "conversation_id": "1596864022548185089"}, {"entities": {"mentions": [{"start": 19, "end": 28, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 139, "end": 153, "username": "TheLancetHaem", "id": "2596297298"}, {"start": 228, "end": 237, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 239, "end": 254, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 259, "end": 267, "username": "OncLive", "id": "43051682"}], "urls": [{"start": 269, "end": 292, "url": "https://t.co/Y2VvbxKI95", "expanded_url": "https://twitter.com/ManniMD1/status/1596546087749586944", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "I'm so grateful to @ManniMD1 for his v. patient mentorship &amp; his skilled guidance in nurturing distraught rage tweets into a piece for @TheLancetHaem! Also pleased to have been the butterfly wing-flutter for an ASH convo w/ @ManniMD1, @AaronGoodman33 and @OncLive. https://t.co/Y2VvbxKI95", "source": "Twitter Web App", "created_at": "2022-11-27T14:42:33.000Z", "edit_history_tweet_ids": ["1596877141836435456"], "author_id": "1302975798304014336", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596546087749586944"}], "id": "1596877141836435456", "conversation_id": "1596877141836435456"}, {"entities": {"mentions": [{"start": 50, "end": 59, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 66, "end": 81, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 112, "end": 127, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 106, "end": 110, "probability": 0.5063, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 253, "end": 276, "url": "https://t.co/EdDe8PL7v7", "expanded_url": "https://twitter.com/chadinabhan/status/1596544838874566658", "display_url": "twitter.com/chadinabhan/st\u2026"}], "hashtags": [{"start": 105, "end": 111, "tag": "ASH22"}, {"start": 226, "end": 247, "tag": "HealthcareUnfiltered"}]}, "text": "Listen to these two who have never had a haircut. @ManniMD1 &amp; @AaronGoodman33 describe their planned #ASH22 @ASH_hematology abstract that you don\u2019t want to miss.\n\nOnly interview together before the meeting. Listen here on #HealthcareUnfiltered \ud83d\udc47\ud83d\udc47\ud83d\udc47\ud83d\udc47 https://t.co/EdDe8PL7v7", "source": "Twitter for iPhone", "created_at": "2022-11-26T22:13:18.000Z", "edit_history_tweet_ids": ["1596628186150096896"], "author_id": "2212735524", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596544838874566658"}], "id": "1596628186150096896", "conversation_id": "1596628186150096896"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 22, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 23, "end": 38, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 39, "end": 54, "username": "ASH_hematology", "id": "84072624"}, {"start": 55, "end": 63, "username": "OncLive", "id": "43051682"}]}, "text": "@chadinabhan @ManniMD1 @AaronGoodman33 @ASH_hematology @OncLive As a metastatic lung cancer patient,kept alive by immunotherapy for almost 8 yrs ( on tx break) u must read these reports carefully. What good is living another month if your QOL sucks?", "source": "Twitter for iPad", "created_at": "2022-11-26T20:54:41.000Z", "edit_history_tweet_ids": ["1596608402473750529"], "author_id": "18792477", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1596544838874566658"}], "id": "1596608402473750529", "in_reply_to_user_id": "2212735524", "conversation_id": "1596544838874566658"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "chadinabhan", "id": "2212735524"}, {"start": 29, "end": 38, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 39, "end": 54, "username": "ASH_hematology", "id": "84072624"}, {"start": 55, "end": 63, "username": "OncLive", "id": "43051682"}]}, "text": "@AaronGoodman33 @chadinabhan @ManniMD1 @ASH_hematology @OncLive Hair: Manni &gt;&gt;&gt;&gt;&gt; Aaron \ud83e\udd23\ud83e\udd23", "source": "Twitter for Android", "created_at": "2022-11-26T18:43:18.000Z", "edit_history_tweet_ids": ["1596575339895214080"], "author_id": "75550503", "lang": "hi", "referenced_tweets": [{"type": "replied_to", "id": "1596566142126272512"}], "id": "1596575339895214080", "in_reply_to_user_id": "854692626015993857", "conversation_id": "1596544838874566658"}, {"text": "Check out work out that will be highlighted at the 2022 ASH Poster Walk on Diversity,Equity,and Inclusion\nIt covers a very important topic\n#MedTwitter #ASH22 #AcademicTwitter \nAnalysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals\n\u27a1\ufe0fhttps://t.co/NVuYlDV8Zh\n\ud83e\uddf5 https://t.co/zAau2OXVs3", "source": "Twitter for iPhone", "entities": {"annotations": [{"start": 56, "end": 58, "probability": 0.5867, "type": "Other", "normalized_text": "ASH"}, {"start": 140, "end": 149, "probability": 0.7759, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 159, "end": 173, "probability": 0.6737, "type": "Other", "normalized_text": "AcademicTwitter"}], "urls": [{"start": 254, "end": 277, "url": "https://t.co/NVuYlDV8Zh", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157443.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Analysis of Repeated Roles in Editorial Boards at Oncology-Focused Journals", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster I Hematology Disease Topics & Pathways: Workforce, Diversity, Equity, and Inclusion (DEI) Lama Sawalha, MD 1 *, Ghulam Rehman Mohyuddin, MD 2, Aaron M Goodman 3, Nico Gagelmann 4 *, Amar H Kelkar, MD 5 and Samer Al Hadidi, MD, MSc 6 1 Hashemite University, Amman, Jordan 2 Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT 3 University of California San Diego Moores Cancer Center,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157443.html"}, {"start": 280, "end": 303, "url": "https://t.co/zAau2OXVs3", "expanded_url": "https://twitter.com/HadidiSamer/status/1596561188954943488/photo/1", "display_url": "pic.twitter.com/zAau2OXVs3", "media_key": "3_1596561185327009793"}], "hashtags": [{"start": 139, "end": 150, "tag": "MedTwitter"}, {"start": 151, "end": 157, "tag": "ASH22"}, {"start": 158, "end": 174, "tag": "AcademicTwitter"}]}, "created_at": "2022-11-26T17:47:04.000Z", "edit_history_tweet_ids": ["1596561188954943488"], "author_id": "774267564", "lang": "en", "id": "1596561188954943488", "conversation_id": "1596561188954943488"}, {"entities": {"mentions": [{"start": 38, "end": 47, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 54, "end": 69, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 134, "end": 149, "username": "ASH_hematology", "id": "84072624"}, {"start": 172, "end": 180, "username": "OncLive", "id": "43051682"}], "annotations": [{"start": 151, "end": 155, "probability": 0.502, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 285, "end": 308, "url": "https://t.co/BUP2FokWKF", "expanded_url": "https://twitter.com/chadinabhan/status/1596544838874566658/video/1", "display_url": "pic.twitter.com/BUP2FokWKF", "media_key": "7_1596544597517287425"}], "hashtags": [{"start": 78, "end": 99, "tag": "HealthcareUnfiltered"}, {"start": 150, "end": 156, "tag": "ASH22"}]}, "text": "Zero editing.\nZero filter.\n\nThese two @ManniMD1 &amp; @AaronGoodman33 come on #HealthcareUnfiltered for a 10 mins blitz talking their @ASH_hematology #ASH22 abstract about @OncLive data.\n\nListen to these two explain their findings ahead of the meeting,\nYour BEST 10 mins weekend video https://t.co/BUP2FokWKF", "source": "Twitter for iPhone", "created_at": "2022-11-26T16:42:06.000Z", "edit_history_tweet_ids": ["1596544838874566658"], "author_id": "2212735524", "lang": "en", "id": "1596544838874566658", "conversation_id": "1596544838874566658"}, {"entities": {"mentions": [{"start": 154, "end": 166, "username": "NamSharmaMD", "id": "1131320725682434049"}], "annotations": [{"start": 191, "end": 195, "probability": 0.6297, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/TUXXrgex80", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website", "description": "Program: Oral and Poster Abstracts Session: 903. Health Services and Quality\u2013Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), drug development, Therapies, therapy sequence Naman Sharma, MD 1, Cole Wayant, MD 2 *, Karun Neupane, MBBS 3, Jyotirmayee Lenka, MD 4 *, Katherine Berger 5 *, Aaron Goodman, MD 6 *, Christopher Booth, MD 7 *, Vinay Prasad, MD 8 * and Ghulam Rehman Mohyuddin, MD 9 * 1 Department of Hematology- Oncology, University", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper167903.html"}, {"start": 274, "end": 297, "url": "https://t.co/s9SQO4i2j8", "expanded_url": "https://twitter.com/chadinabhan/status/1596544838874566658", "display_url": "twitter.com/chadinabhan/st\u2026"}], "hashtags": [{"start": 20, "end": 41, "tag": "HealthcareUnfiltered"}, {"start": 190, "end": 196, "tag": "ASH22"}]}, "text": "A pleasure being on #HealthcareUnfiltered to discuss the problem of hype in oncology news media reporting. Potential solutions discussed, look forward to @NamSharmaMD presenting our work at #ASH22, and sharing manuscript once accepted.\n\nOur poster:\n\nhttps://t.co/TUXXrgex80 https://t.co/s9SQO4i2j8", "source": "Twitter Web App", "created_at": "2022-11-26T16:45:28.000Z", "edit_history_tweet_ids": ["1596545686903873536"], "author_id": "1269642863924609025", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1596544838874566658"}], "id": "1596545686903873536", "conversation_id": "1596545686903873536"}]}, "meta": {"next_token": "7140dibdnow9c7btw424cardrtwgu9aczp5cl83izn4ty", "result_count": 100, "newest_id": "1601401559472304130", "oldest_id": "1596545686903873536"}, "neighbors": ["854692626015993857", "3078258341", "2212735524", "1269642863924609025", "844232399319941122", "84072624", "24261916", "75550503"]}